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[57] ABSTRACT 
Peptidyl derivatives of diesters of a-arninoalkylphosphonic 
acids, particularly those with praline or related structures, 
their use in inhibiting serine proteases with chymotrypsin-
like, trypsin-like, elastase-like, and dipeptidyl peptidase IV 
specificity and their roles as anti-inflammatory agents, anti-
coagulants, and anti-tumor agents. 
13 Claims, No Drawings 
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PROLINE PHOSPHONATE DERIVATIVES 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with government support under 5 
Grants No. HL34035 and HL29307 awarded by the National 
Heart, Lung and Blood Institute of the National Institutes of 
Health. The United States government may have certain 
rights in this invention. 
2 
frequency of Gly-Pro sequences. DPP-IV in human plasma 
has been shown to cleave N-terminal Tyr-Ala from growth 
hormone-releasing factor and cause inactivation of this 
hormone. DPP-IV is also involved in T-cell activation and 
regulation ofT-cell proliferation. Thus, inhibitors ofDPP-IV 
may have therapeutic utility in the modulation of the rejec-
tion of transplanted tissue by the host organism. Recently 
DPP-IV or CD26 has been postulated to act as a cofactor for 
entry into HIV in CD4+ cells (Callebaut, C., Krust, B., 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
10 Jacotot, E., Hovanessian, A. G. T cell activation antigen, 
CD26, as a cofactor for entry of HIV in CD4+ cells. Science. 
1993, 262, 2045-2050). Thus inhibitors of DPP-IV should 
have therapeutic utility in the treatment of AIDS. This invention relates to a novel class of peptidyl deriva-
tives of aromatic diesters of a-aminoalkylphosphonic acids 
useful for selectively inhibiting elastase, selectively inhib- 15 
iting chymotrypsin-like enzymes, selectively inhibiting 
trypsin-like enzymes and selectively inhibiting dipeptidyl 
peptidase IV (DPP-IV). The diesters of a-aminoalkylphos-
phonic acids are analogues of natural a-amino acids. This 
invention also relates to a method for controlling tumor 20 
invasion, treating inflammation and controlling blood 
coagulation in patients using the novel compounds of the 
present invention. We have found that peptidyl derivatives 
BRIEF SUMMARY OF THE INVENTION 
The proline phosphonates derivatives of this invention 
have the following general structure: 
x 
(N I oz 
I -\ / p 
AA ~ \ 
and 
<'x N-< OZ I / p 
AA ~ \ 
of aromatic diesters of a-aminoalkylphosphonic acids are 
potent inhibitors of chymotrypsin-like enzymes, elastases, 25 
blood coagulation enzymes, tryptases, kallikreins, and there-
fore they are useful as anti-tumor, anti-inflammatory and 
anticoagulant agents. We have also found that dipeptide 
proline phosphonates are inhibitors of dipeptidyl peptidase 
IV (DPP-IV, enzyme number EC 3.4.14.5, also known as 30 
CD26) and are thus useful in treatment of immune system 
disorders and acute respiratory distress syndrome (AIDS). 
o oz1 o oz1 
or a pharmaceutically acceptable salt thereof, wherein Z and 
Z1 are the same or different and are selected from the group 
consisting ofC1_6 perfluoroalkyl, phenyl, phenyl substituted 
with J, phenyl disubstituted with J, phenyl trisubstituted with 
J, and pentafluorophenyl; J is selected from the group 
consisting of halogen, cl-6 alkyl, cl-6 perfluoroalkyl, cl-6 
2. Description of the Related Art 
Serine proteases play critical roles in several physiologi-
cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, and reproduction. Serine pro-
teases are not only a physiological necessity, but also a 
potential hazard if they are not controlled. Blood coagula-
tion serine proteases are responsible for vascular clotting, 
cerebral infarction and coronary infarction. Chymotrypsin-
like enzymes and plasmin are involved in tumor invasion, 
tissue remodeling, and clot dissociation. Uncontrolled pro-
teolysis by other serine proteases such as elastase may cause 
pancreatitis, emphysema, rheumatoid arthritis, inflammation 
and adult respiratory distress syndrome. Accordingly, spe-
cific and selective inhibitors of these proteases should be 
potent anticoagulants, anti-inflammatory agents and anti-
tumor agents useful in the treatment of protease-related 
diseases. In vitro proteolysis by trypsin, chymotrypsin or the 
elastase family is a serious problem in the production, 
purification, isolation, transport or storage of peptides and 
proteins. 
Dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5, CD26) is 
a post-proline cleaving enzyme which will remove the 
dipeptides AA-Pro (AA=amino acid residue) from the N-ter-
minus of proteins or polypeptides. DPP-IV has been found 
alkoxy, N02 , CN, OH, C02H, amino, C1_6 alkylamino, C2_12 
dialkylamino, C1_6 acyl, and C1_6 alkoxy-CO-, and C1_6 
alkyl-S-; X is selected from the group consisting of (a) a 
35 single bond, (b)-CH2-, (c) -CH2CH2-, (d) 
-CH2CH2CH2-, (e) -CH2CH2CH2CH2-, (f) -Y-, 
(g) -CH2-Y-, (h) -Y-CH2-, and (i) -H, H-, 
wherein Y is 0 or S; and AA is selected from the group 
consisting of (a) the structure NH2-CHR-CO-where R 
40 is selected from the group consisting of cl-6 alkyl and cl-6 
fluorinated alkyl, (b) a side chain blocked or unblocked 
alpha amino acid residue with the L, D or DL configuration 
at the a-carbon atom selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methionine, 
45 methionine sulfoxide, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutarnine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, citrul-
line, hydroxyproline, ornithine, homoarginine, O-meth-
50 ylserine, 0-ethylserine, S-methylcysteine, S-ethylcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2)-COOH, 
alphaaminoheptanoic acid, NH2-CH(CH2- l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, NH2-
CH(CHz-cyclohexyl)-COOH, NH2-CH(CH2-cyclopen-
55 tyl)-COOH, NH2-CH(CH 2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, 5,5,5-trifluoroleu-
cine, and hexafluoroleucine, (c) an amino acid residue 
selected from the group consisting of beta-alanine, glycine, 
epsilon-aminocaproic acid, and sarcosine, (d) H, and (e) 
60 C6H5CH20CO-. 
in a variety of mammalian cells and tissues including kidney, 
placenta, blood plasma and on the surface of certain T-lym-
phocyte subsets. Despite extensive studies, the biological 
role of DPP-IV in mammalian systems has not been com-
pletely established, although a number of functions have 
been postulated. DPP-IV may participate in the metabolism 
and uptake of proline-containing peptides in the intestine 
and kidney and may be involved in fibronectin-mediated cell 65 
movement and adhesion. DPP-IV may also play a role in the 
metabolism or catabolism of collagen which has a high 
A therapeutically effective amount of these compounds 
can be used to inhibit dipeptidyl peptidase IV in mammals. 
A therapeutically effective amount of these compounds 
can be used to treati AIDS in mammals. 
A therapeutically effective amount of these compounds 
can be used to prevent tissue transplant rejection in mam-
mals. 
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It is an object of this invention to define a novel group of 
specific inhibitors for trypsin, elastase, chymotrypsin and 
other serine proteases. Inhibitors are compounds that can 
reduce or eliminate the catalytic activity of the enzyme. 
Trypsin and trypsin-like enzymes normally cleave peptide 5 
bonds in proteins and peptides where the amino acid residue 
on the carbonyl side of the split bond (P1 residue) is Lys or 
Arg. Elastase and elastase-like enzymes cleave peptide 
bonds where the P 1 amino acid is Ala, Val, Ser, Leu and 
other similar amino acids. Chymotrypsin and chymotrypsin- 10 
like enzymes hydrolyze peptide bonds where the P 1 amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid residue 
which contain an aromatic or large alkyl side chain. All of 
the above enzymes have extensive secondary specificity and 
recognize amino acid residues removed from the P1 residue. 15 
It is a further object of this invention to define new 
protease inhibitors, especially inhibitors for chymotrypsin 
and chymotrypsin-like enzymes, elastase inhibitors, blood 
coagulation enzyme inhibitors and tryptase inhibitors. These 
inhibitors are useful for controlling tumor invasion, blood 20 
coagulation and various inflammatory conditions mediated 
by serine proteases. The inhibitors of this invention are 
useful for treating diseases such as vascular clotting, inflam-
mations, tumor invasion, pancreatitis, emphysema or infan-
tile and adult respiratory distress syndrome. The inhibitors 25 
of this invention are also useful for controlling hormone 
processing by serine proteases and for treating diseases 
related to tryptases such as inflammation and skin blistering. 
It is yet another object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 30 
trypsin, elastase, chymotrypsin and other serine proteases of 
similar specificity. Such inhibitors could be used to identify 
new proteolytic enzymes encountered in research. They can 
be used in research and industrially to prevent undesired 
proteolysis that occurs during the production, isolation, 35 
purification, transport and storage of valuable peptides and 
proteins. Such proteolysis often destroys or alters the activ-
ity and/or function of the peptides and proteins. Uses can 
include the addition of the inhibitors to antibodies, enzymes, 
plasma proteins, tissue extracts or ·Other proteins and pep- 40 
tides which are widely sold for use in clinical analyses, 
biomedical research, and for many other reasons. 
It is yet another objective of this invention to define a 
novel group of specific inhibitors for DPP-IV. The inhibitors 
are useful for controlling the immune system, inhibiting the 45 
process of organ transplant rejection, for treatment of AIDS, 
and related disorders. 
These and other objects are accomplished by the present 
invention which defines novel peptidyl derivative of aryl 
diesters of a-aminoalkylphosphonic acids. These phospho- 50 
nate derivatives are potent inhibitors of serine proteases 
including chymotrypsin-like enzymes, trypsin-like 
enzymes, elastase-like enzymes, DPP-IV and other enzymes 
with other substrate specificities. The phosophonates are 
stable in buffer or plamsa, and inhibit the serine proteases to 55 
give stable inhibited enzyme derivatives. The phosphonates 
can be used both in vitro and in vivo. 
DETAILED DESCRIPTION OF THE 
INVENTION 60 
Peptidyl derivatives of aryl diesters of a-aminoalkylphos-
phonic acids have be found to be excellent inhibitors of 
several serine proteases including bovine thrombin, human 
factor Xlla, human plasma kallikrein, bovine trypsin, rat 65 
skin tryptase, human leukocyte elastase, porcine pancreatic 
elastase, bovine chymotrypsin, human leukocyte cathepsin 
4 
G, DPP-IV, and rat mast cell protease II. The diesters of 
a-aminoalkylphosphonic acids are analogues of natural 
a-amino acids and are designated by the generally accepted 
three letter abbreviations for the amino acid followed by the 
superscript P. For example diphenyl a-(N-benzyloxycarbo-
nylamino)ethylphosphonate which is related to alanine is 
abbreviated as Cbz-AlaP(OPh)z. 
CH3 OPh 
I I 
Bzl-0-CO-NH-CH-P 
II\ 
0 OPh 
Complete Structure of Cbz - AlaP(OPhh 
Peptidyl derivatives of aryl diesters of a-aminoalkylphos-
phonic acids inhibit serine proteases by reaction with the 
active site serine to form "phosphonylated" enzymes, which 
due to the similarity of phosphorus atom to the tetrahedral 
intermediate formed during peptide hydrolysis, show 
remarkable stability. The enzyme catalytic apparatus is 
required to activate the phosphorus atom for nucleophilic 
substitution and reaction with enzyme. The activation is 
mainly due to precise interaction with the S1 pocket of 
various serine proteases. The following figure shows the 
reaction course of a phosophonate with a serine protease. 
The phosphonate first binds to the enzyme (below left) and 
then reacts to form a covalent bond with the active site serine 
residue (below right). Slow aging can take place with loss of 
the phenoxy group (below center). 
Substrate 
Binding Site 
Active Site 
Ser195 
I 
O-H--·His57 
R OPh 
I I 
R-CO-NH-CH-P 
II\ 
0 OPh 
Active Site 
I 
Ser195 
R 0 H-His51 
I I 
R-CO-NH-CH-P 
II\ 
Aging> 
0 ·,?Ph 
H H I I oxyanion 
N N hole 
Active Site 
/er195 
R 0 H-His57 
I I 
R-CO-NH-CH-P 
II\ 
0 o-
H 
I 
N 
H I oxyanion 
N hole 
Peptides with a C-terminal phosphonate residue which is 
an analog of valine (e.g. ValP(OPh}i) are potent and specific 
irreversible inhibitors of elastase and elastase-like enzymes. 
The peptides with C-terminal phosphonate residues related 
to phenylalanine, other aromatic amino acids or amino acids 
with long aliphatic side chains are potent and specific 
5,543,396 
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inhibitors of chymotrypsin and chymotrypsin-like enzymes. 
The peptides with C-terminal phosphonate residues related 
to omithine, arginine or containing a C-terminal diphenyl 
ester of a-amino-a-( 4-amidinophenyl)methanephosphonate 
are specific and potent inhibitors of trypsin and trypsin-like 5 
enzymes. Dipeptides with the C-terminal phosphonate resi-
dues related to proline or homoproline are specific and 
potent inhibitors of DPP-IV. The structures of two inhibitors 
are shown below. The dipeptide phosphonate on the left has 10 
a proline phosphonate derivative (abbreviated -Prop-) at the 
C-terminal end of the dipeptide, while the derivative on the 
right has a homoproline phosphonate (or piperidyl phospho-
nate, abbreviated -PipP-) as the C-terminal residue. 
6 
Examples of phosphonate inhibitors for various enzymes 
are given below: 
Cbz-Gly-Leu-PheP(OZ), 
Me0-Suc-Ala-Ala-Pro-Met:1'(0Z), 
Suc-Pro-Leu-PheP(OZ), 
and Boc-Ala-Ala-PheP(OZ)2 
Boc-Gly-Leu-PheP(OZ),, 
Suc-Phe-Leu-PheP(OZ), 
Boc-Ala-Ala-GluP(OZ), 
Cbz-Gly-Gly-ProP(OZ)z 
Ala-ProP(OZ), 
Suc-Ala-Ala-Pro-VaJP(OZ), 
for cathepsin G and 
RMCP II 
for Cathepsin G 
for RMCP I 
for human and dog 
skin chymase 
for S. aureus V-8 
protease 
for human prolyl 
endopeptidase 
for DPP IV 
for PPE 
15 Suc-Lys(Cbz)-Val-Pro-VaJP(OZ),, for human leukocyte 
(neutrophil) elastase 
AA - ProP(QAr)i 
AA-Pip1'(0Arh 
adamantyl-S02-
Lys(COCH2CH2C02H)-Ala-
VaJP(OZ)z,adamantyl-CH2CH20CO-
Glu(O-t-Bu)-Pro-ValP(OZ),, 
adamantyl-S02-Lys(CO-C6H4C02H)-
20 Ala-ValP(OZ), 
Suc-Ala-Ala-Pro-LeuP(QZ)2 
Glu-Phe-X and Dns-Ala-Phe-X 
D-Val-Gly-X and Dns-Glu-Gly-X 
25 Cbz-Phe-X and Cbz-Trp-X 
Cbz-Lys-X 
Cbz-Gly-X 
30 Cbz-Ile-Ala-Gly-X 
Glu-Gly-X 
Dns-Phe-Pro-X 
for elastolytic pro-
teinase from "Schis-
tosoma mansoni" 
for plasmin 
for factor Xa 
for porcine pancrea-
tic and human plas-
ma k:allikreins 
for human skin 
tryptase 
for human lung 
tryptase 
for factors IXa, Xa, 
Xla, XIIa and bo-
vine plasma kalli-
krein 
for urokinase 
Additional specificity as well as increased activation 
toward reaction with the enzyme can be introduced into the 
inhibitor molecule by variation of the amino acid sequence 
35 in the peptide portion of the structure. In fact there is a good Dns-Ile-Pro-X 
for plasminogen ac-
tivator 
for activated protein 
c agreement between the sequence of enzyme substrates such 
as a peptidyl p-nitroanilides and the sequence of an effective 
peptidyl phosphonate inhibitor. The best inhibitors have the 
Cbz-Trp-X 
Cbz-Gly-X 
for bovine factor 
IX a 
40 
sequence of the best peptidyl p-nitroanilide substrate for a Cbz-Phe-X 
for bovine factor Xa 
and Xla 
for bovine factor 
XIIa particular enzyme. For example, the best inhibitor for chy-
motrypsin and chymotrypsin-like enzymes is Suc-Val-Pro-
PheP(OPhh which has an amino acid sequence that is 
analogous to Suc-Val-Pro-Phe-NA, an excellent substrate 45 
for these enzymes. With human leukocyte elastase, the two 
best inhibitors (MeO-Suc-Ala-Ala-Pro-ValP(OPhh and 
Boc-Val-Pro-ValP(OPhh) have an amino acid sequence 
similar to MeO-Suc-Ala-Ala-Pro-Val-NA and Boe-Val-Pro- 50 
Cbz-Phe-Gly-X for trypsin 
where Z represents an aryl group, a substituted aryl group or 
a highly fluorinated alkyl group and X represents Ar~(OZ)z 
or an aryl diester of a-amino-a-(4-amidinophenyl)metha-
nephosphonate [NH2-CH(AmPh)PO(OZ)z]. 
The inhibitory potency of peptidyl derivatives of aryl 
diesters of a-aminoalkylphosphonic acids is also determined 
by the electronic property of the Z group. More electron 
withdrawing groups such as nitro, cyano, halogen, etc. on Val-NA, two excellent substrates for this enzyme. For 
bovine thrombin, the best phosphonate inhibitor is diphenyl 
Boc-D-Phe-Pro-amino(4-amidinophenyl) methanephospho-
nate hydrochloride, which corresponds to Boc-D-Phe-Pro-
Arg-NA, which is excellent substrate for thrombin, and 
D-Phe-Pro-Arg-H which is an excellent peptide aldehyde 
inhibitor of thrombin and an anticoagulant. Since good 
substrate sequences are known in the literature for other 
serine proteases, it is possible to predict the structure of 
additional excellent phosphonate inhibitors for these 
enzymes. It is also possible to design good phosophonate 
inhibitors for serine proteases based on on the peptide 
sequences found in other potent reversible and irreversible 
inhibitors for those same serine proteases reported in the 
literature 
the aryl ring can make the phosphorus atom in the inhibitor 
more electrophilic and accelerate reaction with the active 
site serine of the serine protease. Reactivity toward serine 
55 proteases can also be obtained by using derivatives where 
the Z groups are highly fluorinated alkyl groups. However 
increased reactivity can also result in low chemical stability 
and in extreme cases, compounds may be too hydrolyrically 
unstable for practical purposes if the Z group is too elec-
60 tronegative. Phosphonates where the Z group is not suffi-
ciently electron withdrawing will be chemically very stable 
and will react very slowly with serine proteases or not at all. 
Such non-reactive inhibitors would include derivatives 
where Z is simple alkyl groups (e.g. peptidyl derivatives of 
65 alkyl diesters of a-aminoalkylphosphonic acids). Thus the 
phosphonate ester groups (Z) should represent a balance 
between these two competing factors and we find that 
5,543,396 
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diphenyl esters (Z=Ph) are one way to obtain a balance 
between increased reactivity and stability in solution. 
Diphenyl esters of a-arninoalkylphosphonate can be syn-
thesized by a previously described method (Oleksyszyn et 
al., 1979, Synthesis, 985, incorporated by reference). Di(s- 5 
ubstituted phenyl)esters of a-aminoalkylphosphonate can 
also be prepared by the same procedure using iris(substi-
tuted phenyl) phosphite instead of triphenyl phosphite. Per-
fiuoroalkyl diesters can be synthesized by a method involv-
ing transesterification (Szewczyk et al., Synthesis, 1982, 10 
409-414, incorporated by reference). Alternatively, the syn-
thesis of diesters of a-aminoalkylphosphonic acids and their 
peptides can be performed by esterification of the phospho-
nic acid moiety as described previously (Bartlett et al., 
5 HCl.PipP(OPh-4-F)z 
6 HCl.Ala-ProP(OPh)z 
7 AcOH.Ala-Pipp(OPh)z 
8 
8 AcOH.Ala-PipP(OH)(OPh) 
9 HBr.Phe-ProP(OPh)z 
10 2HBr.Lys-ProP(OPh)z 
11 2HCl.Lys-PipP(OPh)z 
12 HCl.Ala-ProP(OPh-4Cl)z 
13 HCl.Ala-PipP(OPh-4Cl)z 
14 HCl.Ala-PipP(OPh-4-F)z 
c1-
+ HPO(OZ)i ~ 
R' I'\ 
x- +H30N Yoz <dare 
0 p/ 
o~ 'oz 
"Reagents: (a) heat under argon; (b) HC! gas in ether; (c) Cbz-NHCHR'COOH, DCC; 
(d) Pd/C, H2, H+ (e) 30% HBr/AcOH 
Bioorg. Chem., 1986, 14, 356-377, incorporated by refer- 35 
ence). 
The dipeptides which contain 2-pyrrolidylphosphonate 
(proline phosphonate) or 2-piperidylphosphonate (homopro-
line phosphonate) were synthesized using the reactions 
outlined in the following scheme. The proline phosphonate 40 
HCl.ProP(OR)z was synthesized by reaction of diphenyl 
phosphite or di-(4-chlorophenyl) phosphite with 1-pyrroline 
trimer (Petrillo, E. W., Spitzmiller, E. R. Synthesis of 
2-Phosphopyrrolidine and Its Substitution for Proline in an 
Inhibitor of Angiotensin-Converting Enzyme, Tet. Lett. 45 
1979, 51, 4929). Subsequent coupling of HCl.ProP(OR)z 
(HCl.ProP(OPh)z, 1 or HCl.ProP(OPh-4-Cl)z,3) with the 
N-blocked amino acid Cbz-AA-OH using the DCC method 
gave the dipeptide phosphonate Cbz-AA-ProP(ORh 
Deblocking of the dipeptides was accomplished by hydro- 50 
genolysis in the presence of acid or by the use of 30% HBr 
in AcOH to give compounds 6, 9, 10, and 12. Similarly, the 
homoproline derivative PipP(OR)z.HC1(2, 4, or 5) was syn-
thesized by reaction of diphenyl phosphite or di-(4-halophe-
nyl) phosphite with 2,3,4,5-tetrahydropyridine trimer 55 
(Solodenko, V. A., Kukhar, V. P. Synthesis of DL-(2-Pip-
eridyl) Phosphonic Acid, Zh. Obsh. Khim. 1987, 57, 2392). 
The intermediate PipP(OR)i.HCl was then coupled with 
Cbz-AA-OH using the DCC method to give the dipeptides 
Cbz-AA-PipP(OR)i. Subsequent deblocking of Cbz-AA- 60 
PipP(OR)z with hydrogenolysis in the presence of acid or 
HBr in AcOH gave compounds 7, 12, 13, and 14. 
1 HCl.ProP(OPh)z 
The diphenyl phosphonate moiety is very resistent to 
chemical hydrolysis and at pH 7.5 we did not observe any 
hydrolysis after several days (monitored by 31P NMR). 
Furthermore, they show excellent stability in human plasma. 
For example Suc-Val-Pro-PheP(OPh) 2 has a hydrolysis 
half-time in human plasma of about 20 hrs. These experi-
ments demonstrate that the phosphonate inhibitors are 
remarkably stable in buffer and plasma. Thus they can be 
used under a variety of conditions. Phosphonates have the 
additional advantage of being very stable in plasma and will 
have a high effectiveness in 10 vivo due to their long 
lifetimes. Additionally, the inhibitor-enzyme complex is 
very stable and the enzyme did not regain any activity after 
several hours in the case of chymotrypsin and after several 
days no recovery of activity was observed in the the cases of 
elastases and trypsin. These experiments show that it is 
possible to decrease or eliminate the enzyme activity and 
biological function of serine proteases for extended time 
periods. 
Either racemic mixtures of the diphenyl a-aminoalky-
lphosphonate residue or pure diastereomers can be used in 
the inhibitor structures. The racemic compounds are more 
easily synthesized and are obtained from less expensive 
starting materials. The pure optically active a-aminoalky-
lphosphonate derivatives required in the synthesis are more 
difficult to synthesize and require more expensive starting 
materials. In the case of the peptidy 1 phosphonate inhibitors 
which are mixtures of two diastereomers, only one will 
usually react with the enzymes. The pure diastereomers will 
possess higher inhibition rates and could be used at lower 2 (HCl.Pipp(OPh)z 
3 HCl.ProP(OPh-4-Cl)z 
4 HCl.PipP(OPh-4-Cl)2 , 
65 concentrations. 
Peptidyl derivatives of aryl diesters of a-arninoalkylphos-
phonates may be used in vivo to treat diseases resulting from 
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abnormal or uncontrolled blood coagulation or diseases 
caused by uncontrolled proteolysis by elastase, chymot-
rypsin, trypsin and related serine proteases. These inhibitors 
may be used in vitro to prevent proteolysis which occurs in 
the process of the production, isolation, purification, storage 5 
or transport of peptides and proteins. 
dyl peptidase IV in mammals by treatment of a mammal 
with a therapeutically effective amount of the novel phos-
phonate compound. 
The blocking groups which may be present on -HN-
CH(R)-P(O)- or on the amino acid AA are those well 
known in the art of peptide synthesis. The particular choice 
of the blocking group used in the compounds of the inven-
tion depends on several factors, including the blocking 
group's affect on enzyme specificity, its affect on phospho-
nate solubility, and its utility during synthesis. Suitable 
The novel peptidyl derivatives of aryl diesters a-ami-
noalkylphosphonates of the present invention have the fol-
lowing structural formula: 
x 
(N I oz 
I -\I p 
AA ;/ \ 
o oz1 
and 
<'x 
N-< OZ I I p 
AA I/\ 
o oz1 
or a pharmaceutically acceptable salt, wherein 
Z and Z1 are the same or different and are selected from 
the group consisting of cl-6perfiuoroalkyl, phenyl, phenyl 
substituted with J, pheny 1 disubstituted with J, pheny 1 trisub-
stituted with J, and pentafiuorophenyl; 
J is selected from the group consisting of halogen, C1_6 
alkyl, C1_6 perfiuoroalkyl, C1_6 alkoxy, N02, CN, OH, 
C02H, amino, C1_6 alkylamino, C2_12 dialkylamino, C1_6 
acyl, and C1_6 alkoxy-CO-, and C1_6 alkyl-S-; 
X is selected from the group consisting of 
(a) a single bond, 
(b)-CH2-, 
(c) -CH2CH2-, 
(d)-CH2CH2CH2-, 
(e) -CH2CH2CH2CH2-, 
(f)-Y-, 
(g) -CH2-Y-, 
(h) -Y-CH2-, and 
(i)-H, H-, 
wherein Y is 0 or S; and 
AA is selected from the group consisting of 
(a) the structure NH2-CHR-CO- where R is selected 
from the group consisting of cl-6 alkyl and cl-6 
fluorinated alky 1, 
(b) a side chain blocked or unblocked alpha amino acid 
residue with the L, D or DL configuration at the 
a-carbon atom selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, argin-
ine, histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
omithine, homoarginine, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHE~)-COOH, alpha-ami-
noheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, NH2-
CH(CH2-cyclohexyl)-COOH, NH2-CH(CH2-
cyclopentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2-CH(CH2-cyclopropyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine, 
(c) an amino acid residue selected from the group con-
sisting of beta-alanine, glycine, epsilon-aminocaproic 
acid, and sarcosine, 
(d) H, and 
(e) C6H5CH20CO-. 
This invention also includes the use of the novel phos-
phonate compounds described above for inhibiting dipepti-
10 blocking groups include but are not limited to carbobenzy-
loxy (Cbz), benzoyl, t-butyloxycarbonyl (Boe), glutaryl, 
p-tolylsulfonyl (Tos), methoxysuccinyl (MeO-Suc), and 
succinyl. 
The -HN-CH(R)-P(O)- residue is derived from a 
15 blocked or unblocked alpha amino acid residue -HN-
CH(R)-CO- whose alpha carbonyl group has been 
replaced by a P(O) group. The R group is the side chain of 
the alpha amino acid. The alpha amino acid residue is 
derived from natural alpha amino acids such as those listed 
20 in the IUPAC-IUB Joint Commision on Biochemical Nomenclature report on the Nomenclature and Symbolism 
for Amino Acids and Peptides (J. Biol Chem., 260, 14--42 
(1985) incorporated by reference). The choice of the par-
ticular amino acid residue used in the design of the phos-
phonate inhibitor will depend on the enzyme targeted for 
25 inhibition. For example, with chymotrypsin-like enzymes 
which prefer Trp, Tyr, or Phe at the P 1 position of their 
substrates, -TrpP -, Ty?-, and PheP - residues would be 
suitable phosphonate residues to incorporate into the P 1 
position of an inhibitor. With elastase-like enzymes which 
30 prefer Val, Ser, or Ala at the P 1 position of their substrates, 
-ValP -, Se?-, and AlaP - residues would be suitable 
phosphonate residues to incorporate in the P 1 position of an 
inhibitor. Likewise with trypsin-like enzyme -LysP - or 
-Ar~ - residues would be suitable. 
35 
40 
Unnatural blocked or unblocked alpha amino acid resi-
dues can also be used in the design of phosphonate inhibi-
tors. If the target serine protease will hydrolyze a substrate 
containing the unnatural amino acid residue at the P1 posi-
tion or if an inhibitor structure contains the unnatural amino 
acid residue as the P 1 residue, then this residue can be used 
in the design of a phosphonate inhibitor. For example, 
chymotrypsin hydrolyzes parafiuorophenylalanine contain-
ing substrates and thus the -HN-CH(CH2C6H4F)-
P(O)- would be suitable for incoroporating into a chymot-
rypsin inhibitor. Likewise, trypsin will hydrolyze substrates 
45 with aminoethylcystein residues and cathespin G will hydro-
lyze aminopropylcystein residues and thus -HN-
CH(CH2SCH2CH2NH2)-P(O)- and -HN-CH(CH 
2SCH2CH2CH2NH2)-P(O)- would respectively be suit-
able residues to incorporate into inhibitors for trypsin and 
50 cathepsin G. One skilled in the art of designing inhibitors for 
proteolytic enzyme can list many other unnatural amino acid 
residues which could be used in the design of suitable 
inhibitors. 
Other aryl diesters of a-aminoalkylphosphonic acids have 
55 been prepared earlier for other purposes (illustrative 
examples: Oleksyszyn, J. et al., Synthesis, 1979, 985-986.; 
Vo-Quang, Y. et al., J. Med. Chem. 1986, 43, 579-581.; 
Kafarski, P. et al., Tetrahedron, 1987, 43, 799-803.; Szewc-
zyk, J. et al., Synthesis, 1982, 409-414; the preceding 
articles are incorporated herein by reference). 
60 A few other derivatives of a-aminoalkylphosphonic acids 
have been prepared recently for inhibition of serine pro-
teases, but they are not peptidyl derivatives or are peptidyl 
derivatives with the phosphonic acid moiety inside the 
peptide chain (Bartlett et al., Bioorg. Chem., 1986, 14, 
65 356-377, Lamden et al., Biochem. Biophys. Res. Commun., 
1983, 112, 1085-1090; the preceding articles are incorpo-
rated herein by reference). We have published some of our 
5,543,396 
11 
work in a paper Irreversible Inhibition of Serine Proteases 
by Peptidyl Derivatives of a-Aminoalkyl_rhosphon~te 
Diphenyl Esters, Oleksyszyn and Powers, Bwchem. Bw-
phys. Res. Commun. 1989, 161,143-149. Subsequently, Fas-
trez et al., Tetrahedron Lett., 1989, 30, 6861-6864 reported 
phosphonate inhibitors similar to those which we re~orted 
(both the preceding articles are incorporated herem by 
reference). 
The following compounds are representative of but do not 
limit the invention: 
Dipheny 1 amino( 4-amidinophenyl)methane-phosphonate 
dihydrochloride 
(NH2-CH(Am-C6H4)PO(OPh)z) 
Diphenyl N-benzyloxycarbonylarnino(4-arnidinophenyl) 
methanephosphonate hydrochloride 
(Cbz-NH-CH(Am-C6H4)PO(OPh)z) 
Diphenyl N-(N-benzyloxycarbonylprolyl)arnino(4-amidi-
nophenyl)methanephosphonate hydrochloride (Cbz-NH-
Pro-NHCH(Am-C6H4)PO(OPh)2) 
Diphenyl N-(D-Phe-Pro)arnino(4-amidinophenyl)methane-
phosphonate dihydrochloride 
(D-Phe-Pro-NH CH(Am-C6H4)PO(OPh)z) 
Dipheny 1 N-(Boc-D-Phe-Pro )amino( 4-arnidinopheny 1) 
methanephosphonate hydrochloride 
(Boc-D-Phe-Pro-NHCH(Am-C6H4)P0(0Ph)2) 
Diphenyl N-(N-~-napthylsulfonylglycyl)arnino(4-arnidi-
nophenyl)methanephosphonate hydrochloride (Naphthyl-
sulfonyl-Gly-NHCH(Am-C6H4)P0(0Ph)z) 
Cbz-AlaP(OCH2CF3)z 
Cbz-Phep(OCH2CF3 )z 
Cbz-ValP(4-F-C6H40)z 
Cbz-Mer(OPh)2 
Cbz-Met(O)P(OPh)z 
MetP(OPh)z.HBr 
Cbz-NHCH(4-N02-C6H4)PO(OPh)z 
Benzoyl-NHCH(4-NH2-C6H4)P0(0Ph)z 
Cbz-NHCH( 4-CN-C6H4)PO(OPh)z 
NH2CH( 4-N02-C6 H4)PO(OPh)z 
Cbz-NHCH(CH2=CH-)P0(0Ph)z 
Cbz-NHCH(4-C02H-C6H4)P0(0Ph)2 
Cbz-NHCH(3-CH3-C6H4)P0(0Ph)z 
CF3CF2CF2CO-AlaP(OPh)z 
(m-Tos-Phe)-C6H4CO-ValP(OPh)z 
Cbz-Ala-AlaP(OPh)z 
Cbz-Ala-PheP(OPh)z 
Cbz-Ala-ValP(OPh)z 
Cbz-Pro-ValP(OPh)z 
Cbz-Pro-PheP (OPh)z 
Cbz-Phe-PheP (OPh)z 
Cbz-Leu-PheP(OPh)z 
Cbz-Val-PheP(OPh)z 
Cbz-Val-ValP(OPh)z 
Cbz-Pro-ValP ( 4-F-C6H4 O)z 
Cbz-Pro-PheP(OCH2CF3)z 
Cbz-Pro-ValP(OEt)z 
Boc-Pro-PheP(OPh)z 
Boc-Pro-ValP(OPh)z 
Boc-Pro-NvaP(OPh)z 
Ala-AlaP(OPh)z.HBr 
Phe-AlaP(OPh)z.CF3COOH 
Cbz-Ala- Ala-ValP(OPh)z 
Cbz-Phe-Pro-PheP (OPh)z 
Cbz-Val-Val-ValP(OPh)z 
Cbz-Phe-Pro-PheP(OPh)z 
Suc-Phe-Pro-PheP(OPh)z 
Suc-Val-Pro-PheP(OPh)z 
Boc-Val-Pro-ValP(OPh)z 
Boc-Ala-Pro-ValP(OPh)z 
12 
MeO-Suc-Ala-Ala-Pro-Mer(OPh)z 
MeO-Suc-Ala-Ala-Pro-Met(Ot(OPh)z 
MeO-Suc-Ala-Ala-Ala-ValP(OPh)z 
MeO-Suc-Ala-Ala-Ala-NvaP(OPh)z 
5 MeO-Suc-Ala-Ala-Ala-PheP(OPh)z 
MeO-Suc-Ala-Ala-Pro-ValP(OPh)z 
MeO-Suc-Ala-Ala-Pro-PheP(OPh)z 
MeO-Suc-Ala-Ala-Pro-LeuP (OPh)z 
10 MeO-Suc-Ala-Ala-Pro-NvaP(OPh)z 
Di phenyl Pyrrolidine-2-phosphonate 
(HCl.ProP(OPh)z) 
Di phenyl Piperidine-2-phosphonate 
(HCl.Pipp(OPh)z) 
Hydrochloride 
Hydrochloride 
15 Di(4-chlorophenyl)Pyrrolidine-2-phosphonate Hydrochlo-
ride (HCl.ProP(OPh-4-Cl)z) 
Di(4-chlorophenyl)Piperidine-2-phosphonate Hydrochlo-
ride (HCl.PipP(OPh-4-Cl)z) 
Di(4-fiuorophenyl)Piperidine-2-phosphonate Hydrochloride 
20 (HCl.Pipp(OPh-4-F)z) 
Diphenyl Alanylpyrrolidine-2-phosphonate Hydrochloride 
(HCl.Ala-ProP(OPh)z) 
Cbz-Ala-ProP (OPh)z 
25 Ala-PipP(OPh)z 
Ala-PipP(OH)(OPh) 
Cbz-Ala-Pipp(OPh)z 
Phe-ProP(OPh)z 
Cbz-Phe-ProP(OPh)z 
30 Lys-Prop(OPh)z 
Cbz-Lys(Cbz)-ProP(OPh)z 
Lys-PipP(OPh)z 
Cbz-Lys(Cbz)-Pi pP (OPh)z 
Ala-ProP(OPh-4-Cl)z 
35 Cbz-Ala-ProP(OPh-4-Cl)z 
Ala-PipP(OPh-4-Cl)z 
Cbz-Ala-PipP(OPh-4-Cl)z 
Ala-PipP(OPh-4-F)z 
Cbz-Ala-Pipp(OPh-4-F)z 
40 It has been found that compounds of the present invention 
have effective inhibitory activity against DPP-IV as shown 
in Table I. At inhibitor concentrations of 0.12 mM and with 
a 2 min incubation time, only Lys-PipP(OPh)z (11) and 
Ala-PipP(OPh-4-Cl)z (13) effectively inhibited DPP-IV. 
45 With a 30 min incubation time, five dipeptide phosphonates 
(6, 7, 11, 12, 13) showed some inhibitory potency. The 
monoester Ala-PipP(OH)(OPh) (8), compound 9 with Phe at 
the P2 site and 10 did not show any inhibition of DPP-IV 
under these conditions. 
50 
TABLE I 
Inhibition of Human Placenta DPP-IV by Peptidyl Phosphonates• 
[I] % Inhibition 
55 
Inhibitors (mM) 2 min 30 min 
6 HCl.Ala-ProP(OPh)z 0.12 0 33 
7 AcOH.Ala-PipP(OPh)z 0.12 0 100 
8 AcOH.Ala-PipP(OH)(OPh) 0.12 0 0 
60 9 HBr.Phe-ProP(OPh)z 0.12 0 0 
10 2HBr.Lys-ProP(OPh)z 0.12 0 0 
11 2HCl.Lys-PipP(OPh)z 0.12 35 88 
12 HCl.Ala-ProP(OPh-4Cl)z 0.12 0 100 
13 HCl.Ala-PipP(OPh-4Cl)z 0.12 88 100 
65 'Percentage inhibition was measured after 2 or 30 min incubation in 0.05 M 
Tris, pH 7.8 buffer and 5% MezSO and at 23° C. TFA.Ala-Pro-AFC (0.190 
mM) was used as the substrate. 
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The second-order inhibition rate constants k0 b)[I] for the 
better inhibitors are shown in Table II. The best inhibitor was 
Ala-PipP(OPh-4-Cl)2 (13). Substitution of phenoxy by a 
4-chlorophenoxy group improves the inhibition rate by 
12-23 fold (12>6; 13>7). However, the inhibition rate of 5 
DPP-IV by compound 14 containing a 4-ftuorophenyl group 
TABLE III-continued 
Inhibition of Proteases and Esterases by Dipeptide Phosphonates• 
Ala- Ala-ProP(OPh- Ala-PipP(OPh-
is similar to the inhibition rate for the unsubstituted phenoxy 
derivative 7. Replacing the Pro phosphonate by a homopro-
line phosphonate (PipP) also enhanced the inhibition by 
2-10 fold (7>6; 11>10; 13>12). Previous studies with syn-
thetic substrates demonstrated that DPP-IV hydrolyzed the 
dipeptide p-nitroanilides AA-Pro-pNA faster when the P2 
site contained a Pro, Abu, Leu, Val, or Ala rather than Phe 
10 
Enzymes 
PPE 
Acetylcholines-
terase 
Papain 
Cathepsin B 
ProP(OPh)z 
(6) 
NI 
NI 
NI 
NI 
4-Cl)z 4-Clh 
(12) (13) 
NI NI 
NI NI 
NI NI 
NI NI 
or Lys. In the Pro or homoproline-containing phosphonate 
inhibitors, Ala is preferred at the P2 site rather than Lys or 15 
Phe. For example, Ala-ProP(OPh)z (6) but not Phe-Pro-
P(OPh)z (9) or Lys-ProP(OPh)z (10) inhibited DPP-IV at 
0.12 mM and 30 min incubation (Table I). Similarly, Ala-
PipP(OPh)2 (11) inhibited DPP-IV more potently than Lys-
PipP(OPh)2 (7). Interestingly, both Pro and homoproline- 20 
containing dipeptide phosphonates inhibited DPP-IV and 
the substitution of a Pro phosphonate by a homoproline 
phosphonate enhanced the inhibition rates. This indicates 
that the S1 pocket of DPP-IV is bigger than a praline ring 
and can accommodate the larger homoproline structure. 25 
•Inhibition was measured in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer (chymotrypsin, PPE, HLE), 0.1 M Hepes, O.Ql M CaCl,, 
pH 7.5 (trypsin), 0.1 M phosphate, pH 7.5 (acetylcholinesterase), 
0.05 M Tris, 2 mM EDTA, 5 mM cysteine, pH 7.5 (papain), or 
0.1 M phosphate, 1.33 mM EDTA, 2.7 mM cysteine, pH 6.0 (cath-
epsin B), 8-9% Me;,SO and at 23° C. Substrates were 
Suc-Phe-Thr-Phe-pNA (0.48 mM) for chymotrypsin, 
Z-Phe-Gly-Arg-pNA (0.Q9 mM) for trypsin, 
MeO-Suc-Ala-Ala-Pro-Val-pNA (0.24 mM) for HLE, 
Suc-Ala-Ala-Ala-pNA (0.44 mM) for PPE. Inhibitor 
concentrations were 0.42 mM. 
hNI, no inhibition after 30 min of incubation of enzyme with 
inhibitor. 
TABLE II 
Rates of Inhibition of OPP-IV by Peptide Phosphonates and 
Half-Lives for Hydrolysis of Peptide Phosphonates• 
t,12 [I] k,,b,/[I] 
Inhibitors (h) (mM) (M-'s-') 
6 HCl.Ala-ProP(OPh)z 23.1 0.42 1.2 
7 AcOH.Ala-PipP(Oph)z >72 0.42 12.6 
10 2HBr.Lys-ProP(OPh)z 52 0.42 1.7 
11 2HCl.Lys-PipP(Oph)z >48 0.42 4.2 
12 HCl.Ala-ProP(OPh-4-Cl)z 5.3 0.42 28 
13 HCl.Ala-PipP(OPh-4-Cl)z 67 0.042 156 
14 HCl.Ala-PipP(OPh-4-F)z >68 0.42 12 
•Hydrolysis and inhibition were measured in 0.05 M Tris, pH 7.8 buffer and 
8% Me;,SO and at 23° C. TFA.Ala-Pro-AFC (0.2 mM) was used as the 
substrate. 
The specificity of these dipeptide phosphonates for DPP-
IV was examined by measuring inhibition rates with other 
proteases and esterases. The results were shown in Table III. 
Three inhibitors Ala-ProP(OPh)z (6), Ala-ProP(OPh-4-Cl)z 
(12), and Ala-PipP (OPh-4-Cl)z (13) inhibited DPP-IV but 
not six other proteases and esterases. Two chlorophenoxy 
phosphonates 12 and 13 inhibited chymotrypsin very slowly, 
which is surprising since chymotrypsin does not hydrolyze 
peptide substrates with Pro at the P 1 site. We postulate that 
one of the two 4-chlorophenoxy groups in inhibitors 12 and 
13 is fitting into the large hydrophobic S1 site of chymot-
rypsin and this result shows in the inhibition rates. With this 
exception, the inhibitors are highly specific for DPP-IV. 
TABLE III 
Inhibition of Proteases and Esterases by Dipeptide Phosphonates• 
Ala- Ala-ProP(OPh- Ala-PipP(OPh-
ProP(OPh)z 4-0)z 4-Cl)z 
Enzymes (6) (12) (13) 
Chymotrypsin Nib 26 18 
Trypsin NI NI NI 
HLE NI NI NI 
Spontaneous Hydrolysis of Dipeptide Phosphonates. Pep-
35 
tide phosphonates are known to be stable in buffer and 
plasma (Oleksyszyn, J., Powers, J.C., Irreversible Inhibition 
of Serine Proteases by Peptide Derivatives of (a-Ami-
noalkyl)phosphonate Diphenyl Esters, Biochemistry 1991, 
30 30, 485-493). Half-lives for hydrolysis of seven phospho-
nates are shown in Table II. These inhibitors are quite stable 
with half-lives of 5.3 to>72 h. Phosphonates with a 4-chlo-
rophenoxy group hydrolyzed faster than those with phenoxy 
group or4-fiuorophenoxy group (t112:6>12; 7, 14>13). Phos-
phonates with homoproline at the P 1 site are more stable 
than those with Pro (t112:7>6; 13>12). 
40 
Inhibition Mechanism. The proposed inhibition mecha-
nism of DPP-IV by the dipeptide phosphonate, Ala-Pip-
P(OPh)z (7), is similar to that previously described for other 
serine proteases (Oleksyszyn, J., Powers, J. C., Irreversible 
Inhibition of Serine Proteases by Peptide Derivatives of 
(a-Aminoalkyl)phosphonate Diphenyl Esters, Biochemistry 
1991, 30, 485-493). It involves the nucleophilic substition at 
the phosphorus atom by the active site Ser-195 through a 
45 pentavalent intermediate to form a phophonylated enzyme. 
The leaving group in these dipeptide phosphonates is an 
electronegative phenoxy or 4-halophenoxy group. The Pro 
or Pip residue fits into the S1 pocket. The DPP-IV which was 
inhibited by compounds 6, 7, 12, or 13 was stable and did 
50 not regain enzyme activity after 24 h. Excess inhibitors in 
the inhibited enzyme solution were removed by centrifuga-
tion of the diluted enzyme solution twice using Amicon 
microconcentrators. These results are consistent with the 
55 
formation of a stable phosphonylated enzyme derivative. 
Inactivation rates of serine proteases by aryl diesters of 
peptidyl derivatives of a-arninoalkylphosphonates were 
measured by the incubation method. An aliquot of inhibitor 
(25 or 50 µI) in Me2SO was added to a buffered enzyme 
solution (0.01-2.3 µM) to initiate the inactivation. Aliquots 
60 (50 µI) were withdrawn at various intervals and the residual 
enzymatic activity was measured. Me2SO concentration in 
the reaction mixture was 8-12% (v/v). A O.lM HEPES, 
O.OIM CaC12, pH 7.5 buffer was utilized for trypsin and 
trypsin-like enzymes. A O.lM HEPES, 0.5M NaCl, pH 7.5, 
was utilized for the other serine proteases. The inhibitor 
concentrations are shown in the Tables I, II, and III. Peptide 
thioesters or peptide nitroanilides with the appropriate 
65 
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sequences were used as substrates for various serine pro-
teases. All peptide thioesters hydrolysis rates were measured 
with the assay mixture containing 4,4'-dithiodipyridine 
(i::324=19800 M-1cm-1). Peptide 4-nitroanilide hydrolysis 
was measured at 410 nm (i::410=8800 M-1cm-1). First order 5 
inactivation rate constants (kobs) were obtained from plots 
of In v /v 0 vs time, and the correlation coefficients were 
greater then 0.98. 
16 
Stability of Inhibited DPP-IV. DPP-IV was inhibited by 
compounds 6, 7, 13, and 14 (0.042-0.42 mM) in the pH 7.8 
buffer. After incubation for I h, no enzyme activity was 
found for inhibitors 7, 13, and 14, and 30% activity was 
found for 6. Excess inhibitors was removed from diluted 
solutions of inactivated enzyme by centrifugation three 
times at 0° C. for 1 h each in Amicon Centricon-10 micro-
concentrators following addition of buffer. The enzyme 
activity of solution was assayed at various intervals as Standard Assay of DPP-IV. DPP-IV was assayed in 450 
IO described above. µL of 50 mM Tris, pH 7.8, 0.2 mM Ala-Pro-AFC (freshly 
diluted from a 20 mM stock in DMF), and 5 µL of enzyme 
solution at 30° C. or in 2 mL of buffer, 0.2 mM Ala-Pro-AFC 
(diluted from 8 mM stock in Me2SO) at 23° C. Fluorescence 
was measured at 400 nm excitation and 505 nm emission. 15 
One unit of DPP-IV is defined as the amount of enzyme that 
will hydrolyze 1.0 µmole of Ala-Pro-AFC per min at 25° C. 
and pH 7.8. 
Enzyme Irreversible Inactivation-Incubation Method. 
An aliquot of inhibitor (25 or 50 µL) in Me2SO was added 20 
to 0.28-0.55 mL of a buffered enzyme solution (0.83 munits 
for DPP-IV; 2.1 units for acetylcholinesterase; 0.07-4.5 µM 
for other enzymes) to initiate the inactivation reaction. 
Aliquots (20-250 µL) were withdrawn at various intervals 
and the residual enzymatic activity was measured at 23° C. 25 
as described below. The buffers were: 0.05M Tris, pH 7.8 for 
DPP-IV; O.lM Hepes, O.OlM CaCl2 , pH 7.5 for bovine 
trypsin; O.lM Hepes, 0.5M NaCl, pH 7.5 for bovine chy-
motrypsin, PPE, and HLE; 0.1 M phosphate, pH 7.5 for 
acetylcholinesterase; 50 mM Tris-HCI, 2 mM EDTA, 5 mM 30 
cysteine, (freshly prepared) pH 7.5 buffer for papain and 100 
mM KH2P04 , 1.33 mM EDTA, 2.7 mM cysteine (freshly 
prepared), pH 6.0 buffer for cathepsin B. The Me2SO 
concentration in the reaction mixtures was 8-9% (v/v). The 
inhibitor concentrations are shown in the appropriate table. 35 
Stock solutions of substrates were prepared in Me2SO and 
stored at -20° C. DPP-IV was assayed with TFA.Ala-Pro-
AFC. Papain and cathepsin B were assayed with Bz-Arg-
AMC and Z-Arg-Arg-AMC, respectively. The release of 
AMC were followed fiuorometrically (excitation at 380 nm 40 
and emmision at 460 nm for AMC). Acetylcholinesterase 
was assayed with acetylthiocholine iodide in the presence of 
DTNB at 412 nm. Trypsin was assayed with Z-Phe-Gly-
Arg-pNA.HCI (0.09 mM), chymotrypsin was assayed with 
Suc-Phe-Thr-Phe-pNA (0.48 mM), PPE and HLE were 45 
assayed with Suc-Ala-Ala-Ala-pNA (0.44 mM) and MeO-
Suc-Ala-Ala-Pro-Val-pNA (0.24 mM), respectively. Peptide 
p-nitroanilide hydrolysis was measured at 410 nm (i::410=8, 
800 M 1cm-1 ). Pseudo first-order inactivation rate constants 
(kobs) were obtained from plots of In v /v 0 vs time, and the 50 
correlation coefficients were greater than 0.98. 
Detennination of Half-Lives for Spontaneous Hydrolysis 
of Inhibitors in Buffer. An aliquot (40 µL) of the phospho-
nates (5 mM) in Me2SO and 60 µL of Me2 SO were added 
to 1.9 mL of0.05M Tris, pH 7 .8 buffer such that the inhibitor 55 
concentration was 0.1 mM and the Me2SO concentration 
was 10% v/v. The spontaneous hydrolysis was monitored by 
following the increase in absorbance at 270 nm for phos-
phonates with phenoxy groups, at 280 nm for compounds 
with 4-.chlorophenoxy groups or at 277 nm for the 4-fiuo- 60 
rophenoxy derivative. Half-lives were obtained from first-
order plots of In (ArA1) vs time, where A, is the absorbance 
of the mixture at time t, and Af is the final absorbance of 
phosphonate monophenyl ester and phenol (or correspond-
ing compounds). This was obtained from the absorbance of 65 
the solution which had remained constant for a few hm;irs. 
All the plots gave correlation coefficients of 0.95 or greater. 
The activity of some proteases correlate directly with the 
invasiveness of tumor cells. The tumor invasion can be 
stopped by treatment with inhibitors of serine proteases. 
Thus the novel inhibitors showed in Table I, Table II and 
Table III will be useful for treatment of tumors. 
The activity of DPP-IV is thought to be one of the 
responsible enzymes in organ transplant rejection, in 
autoimmune diseases, in the pathology of AIDS, and related 
diseases. Thus the novel inhibitors showed in Table I, Table 
II and Table III will be useful for controlling the immune 
system, inhibiting the process of organ transplant rejection, 
for treatment of AIDS, and related disorders. 
For treatment of blood coagulation-related diseases, 
tumor invasion, inflammation, organ transplant rejection, 
AIDS, or for controlling the immune system, the compounds 
of the present invention may be administered orally, topi-
cally or parenterally. The term parenteral as used includes 
subcutaneous injection, intravenous, intramuscular, 
intrastemal injection or infusion techniques. The pharma-
ceutical compositions containing the active ingredient may 
be in the form suitable for oral use, for example as tablets, 
troches, lozenges, aqueous or oily suspension, dispersible 
powders or granules, emulsions, hard or soft capsules or 
syrups or elixirs. Dosage levels of the order to 0.2 mg to 140 
mg per kilogram of body weight per day are useful in the 
treatment of above-indicated conditions (10 mg to 7 gms per 
patient per day). The amount of active ingredient that may 
be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and 
the particular mode of administration. 
To use the above inhibitors in vitro, they are dissolved in 
an organic solvent such as dimethylsulfoxide or ethanol, and 
are added to an aqueous solution containing serine pro-
teases. The final concentration of organic solvent should be 
less than 25%. The inhibitors may also be added as solids or 
in suspension. The serine protease inhibitors of this inven-
tion would be useful in a variety of experimental procedures 
where proteolysis is a significant problem. Inclusion of these 
inhibitors in radioimmunoassay experiments would result in 
higher sensitivity. The use of these inhibitors in plasma 
fractionation procedures would result in higher yields of 
valuable plasma proteins and would make purification of the 
proteins easier. The inhibitors disclosed here could be used 
in cloning experiments utilizing bacterial cultures, yeast, and 
cell lines. The purified cloned product would be obtained in 
higher yield. 
The following examples are given to illustrate the inven-
tion and are not intended to limit it in any manner. 
EXAMPLE 1 
Diphenyl N-benzyloxycarbonylamino(4-cyanophenyl) 
methanephosphonate was obtained from 9.75 g of 4-cy-
anobenzaldehyde, 7.65 g ofbenzyl carbamate and 13.5 ml of 
triphenyl phosphite in 20 ml of glacial acetic acid, according 
to the synthetic procedure described earlier (Oleksyszyn J., 
Subotkowska L., Mastalerz P., Synthesis, 1979, 985). Yield 
5,543,396 
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70%; mp. 135°-138° C.; Anal. Calcd. for 
C28H230 5N2P.V2H20: C, 66.27; H, 4.73; N, 5.52. Found: C, 
66.03; H, 4.51; N, 5.49. 
Cbz-NHCH(4-NOz-C6H4)P0(0Ph)z and Cbz-NHCH(3-
Me-C6H4)PO(OPh)z with m.p. of 151°-153° C. and 5 
127°-129° C. respectively were obtained by the same pro-
cedure using the corresponding benzaldehyde. 
Dipheny 1 N-benzy loxycarbony lamino( 4-arnidinopheny 1)-
methanephosphonate hydrochloride. A solution of 7 g diphe-
nyl N-benzyloxycarbonylarnino( 4-cyanophenyl)-methane- 10 
phosphonate in 150 ml of dry chloroform and 15 ml of 
absolute ethanol was saturated with dry HCI at 0° C. The 
mixture was kept in the refrigerator until TLC (thin layer 
chromatography) showed the absence of starting material 
(about 24 hrs). An excess of pentane was added and the 15 
precipitated solid was removed by filtration and dried using 
a vacuum line. The solid was dissolved in 200 ml of dry 
methanol and gaseous dry ammonia was passed through the 
solution (one equivalent is required) for about 20 min. 
Methanol and excess ammonia was removed quickly on a 20 
rotary evaporator. A 100 ml portion of fresh methanol was 
added and solution was heated at 50° C. for about 8 hrs until 
the TLC shows the absence of imino ether. The solvent was 
evaporated and the resulting oil was dissolved in chloro-
form. Addition of ether caused the oil to solidify. After 25 
filtration the resulting solid was again dissolved in chloro-
form, the solution was filtered and the solid was precipitated 
by addition of ether. In several experiments, the yields were 
70-80%; mp. 154°-158° C. (decomp); 31PNMR 14.87 ppm. 
Anal. Calcd. for C28H270 5N3ClP.0.3 NH4Cl.H20: C, 57.41; 30 
H, 5.16; N, 7.52; Cl, 7.31. Found: C, 57.75; H, 5.00; N, 8.86; 
Cl, 7.43 
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C,51.85; H, 4.97; N, 9.08; Cl, 15.34. Found: C, 51.73; H, 
5.02; N, 9.10; Cl, 15.36. 
AlaP(4-F-C6H40)z.HCl, ValP(4-Me-C6H40)z.HCl, 
PheP(4-Cl-C6H40)z.HCl can be prepared by the same pro-
cedure. 
In general, NH2-CH(R)-P(O)(OZ)(OZ1) hydrochloride 
can be prepared from Cbz-NH-CH(R)-P(O)(OZ)(OZ1) 
using the same procedure. This intermediate can then be 
used to prepare a great variety of derivatives by reaction 
with acylating agents, carbamylating agents, sulfonylating 
agents, chloroformates, or by coupling with a variety of 
peptides and blocked peptides using standing peptide cou-
pling reactions, many of which are illustrated in the follow-
ing examples. 
Diphenyl N-(N-benzyloxycarbonylprolyl)amino(4-arni-
dinophenyl)methanephosphonate hydrochloride. To 0.5 g (2 
mmol) of N-benzyloxycarbonylproline in 3 ml of dry DMF 
at 0° C., 0.45 g (2.77 mmol) of CDI was added and the 
reaction mixture was stirred at 0° C. for 1 hr. Then 0.9 g (2 
mmol) of diphenyl arnino(4-arnidinophenyl)methanephos-
phonate hydrochloride was added. After stirring by 18 hrs at 
0°-5° C., 10 ml of water was added. The oil which precipi-
tated was washed with water and solidified by washing with 
a cold O. lN solution of HCI. One gram of compound was 
obtained which was used without purification in the next 
step. 31P NMR 12.31, 12.62 (free base) and 15.11, 15.41 
ppm (hydrochloride). After addition of one drop concen-
trated HCl to the NMR tube, 14.22, 14.54 ppm (ratio 1:1). 
Benzoyl-Ala-ValP(OPh)z, Formyl-Ala-ValP(OPh)z, 
Fmoc-Ala-ValP(OPh)2 [Fmoc, 9-fluorenylmethyloxycarbo-
nyl], PhNHCO-Ala-Valp(OPh)z, PhNHCS-Ala-ValP(OPh)z, 
Dansyl-Ala-ValP(OPh)z, Tosyl-Ala-ValP(OPh)z, Trityl-Ala-
ValP(OPh)z, Phthaloyl-Ala-ValP(OPh)z, Cbz-Pro-AlaP(4-F-
C6H40)z, Cbz-Pro-Valp (4-Me-C6H40)2, Cbz-Pro-ValP(3-EXAMPLE 2 
35 Cl-C6H40)z, Cbz-Pro-PheP(4-Cl-C6H40)z, Cbz-Pro-
Cbz-ValP(4-F-C6H40)z. Tris(4-fiuorophenyl) phosphite 
was prepared by a previously described method (Walsh, J. 
Am. Chem. Soc. 1959, 81, 3023-3031). Cbz-ValP( 4-F-
C6H40)z was obtained from 6.8 ml of isobutyraldehyde 
(0.075 mole), 7.65 g benzyl carbamate (0.05 mole) and 18.2 40 
g oftris(4-fluorophenyl) phosphite in 10 ml of glacial acetic 
acid as described in example 1, mp. 94 ° -96° C. Anal. Calcd. 
for C24H24N05PF2: C, 60.63; H, 5.05; N, 2.95. Found C, 
60.84; H, 5.11; N, 2.90. 
Cbz-AlaP(4-Me-C6H40)z, Cbz-AlaP(4-Cl-C6H40)z, 45 
Cbz-AlaP(3,4-dichloro-C6H30)2, Cbz-AlaP(4-F-C6H40)2, 
Cbz-ValP(4-Me-C6H40)z, Cbz-Valp (3,4-dimethyl-
C6H30)2, Cbz-PheP(4-F-C6H30)z, Cbz-PheP(3,4-dimethyl-
C6H30)z can be prepared by the same procedure using the 
corresponding tris(substituted-phenyl) phosphite and the 50 
corresponding aldehyde. 
In general, Cbz-NH-CH(R)-P(O)(OZ)(OZ1) can be pre-
pared by reaction of R-CHO with P(OZ)(OZ1 )(OZ2). 
PheP(4-F-C6H40)z, Cbz-Ala-ValP(3-Me-C6H40)z, Cbz-
Ala-PheP(3,4-dichloro-C6H30)z can be prepared by the 
same procedure by coupling with the appropriate blocked 
amino acid or amino acid derivative. 
EXAMPLE4 
Diphenyl N-(D-Phe-Pro)arnino(4-arnidinophenyl)metha-
nephosphonate dihydrochloride. One gram of derivative 
obtained in the previous experiment was hydrogenated in IN 
solution of HCl in methanol with 0.1 g 5% Pd/C, until the 
theoretical amount of hydrogen was consumed. After filtra-
tion of the catalyst and evaporation of the solvent, the 
resulting oil was dried using a vacuum line. A 0.9 g ( 1.64 
mmol) sample of the product dihydrochloridc was added to 
a solution of 0.43 g ( 1.64 mmol) of Boc-D-Phe and 0.34 g 
(2 mmol) of DCI in 2 ml dry DMF, which was allowed to 
react for 1 hrs at 0° C. After 24 hrs 10 ml of water was added 
and the oil which precipitated was decanted. After washing 
with O.lN HCl, the oil which solidified was separated by 
EXAMPLE 3 55 filtration and dried using a vacuum line. The dry solid was dissolved in lN HCl solution in methanol and solution was 
stirred by 1 hr. Solvent was removed on a rotary evaporator 
and the oil was dried using a vacuum line by several hours 
to give 0.3 g of product. Yield 24%; mp. 220°-224° C.; 31P 
60 NMR, 16.95, 17.25, 17,60 ppm (stercoisomcrs and conform-
ers). Anal. Calcd. for C34H380 5N2ClP.5H20: C, 51.78; H, 
6.09; N, 8.88; Cl, 9.00; Found; C, 51.21; H, 5.95; N, 9.04; 
Cl, 8.97. 
Diphenyl amino(4-arnidinophenyl)methanephosphonate 
dihydrochloride. A sample of 1.8 g of diphenyl N-benzy-
loxycarbonylarnino(4-arnidinophenyl)methanephosphonate 
hydrochloride was dissolved in 150 ml of 2N HCl methanol 
solution and after addition of 5% Pd/C catalyst, the solution 
was stirred under an atmosphere of hydrogen until the 
theoretical amount of hydrogen was consumed. The catalyst 
was removed by filtration and after evaporation of the 
methanol, the residue was crystallized from ethanol-ether. In 65 
several experiments, the yields were 60-80%; mp. 
213°-215° C.; Anal. Calcd. for C20H22N3ClP.V2H20: 
EXAMPLES 
Diphenyl N-(Boc-D-Phe-Pro)arnino(4-arnidinophenyl) 
meth:inephosphonate hydrochloride. To 0.36 g (1.0 mmol) 
5,543,396 
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ofBoc-D-Phe-Pro-OH in 2 ml of dry DMF at 0° C., 0.17 g 
( 1.05 mmol) of CDI was added. After stirring for 1 hr at 0° 
C., 0.45 g ( 1.0 mmol) of dihydrochloride of diphenyl 
amino(4-amidinophenyl)methanephosphonate was added 
and the solution was stirred for 48 hrs at 0° C. Water (10 ml) 5 
was added and the oil which precipitated out was decanted 
and washed with distilled water. The oil was dissolved in 
chloroform and the solution was washed with 4% NaHC03, 
water, and 0.05N HCI. After drying over MgS04 , the solvent 
was removed and the resulting oil was dried on a vacuum 10 
line for a few hours to give 0.22 g of product. Yield 29%; 
mp. 185°-190° C.; 31P NMR, 12.42, 12.66, 12.79 ppm 
(stereoisomers and conformers) (free base); 15.12, 15.38, 
15.58 (hydrochloride). Anal. Calcd. for 
C39H450 7N5CIP.V2H20: C, 60.75; H, 5.97; N, 9.08; Cl, 4.60. 15 
Found: C, 60.98; H, 6.48; N, 8.26; Cl., 4.26. 
Tosyl-D-Phe-Pro-ArgP(OPhh, Cbz-D-Phe-Pro-Arg-
P(OPhh, Boc-D-Phe-Pro-ArgP(OPhh, Boc-D-Phe-Pro-
OmP(OPhh, Boc-D-Phe-Pro-ArgP(4-F-C6H40)2, Boc-D-
Phe-Pro-ArgP (4-Me-C6H40h, Boc-D-Phe-Pro-ArgP(3,4- 20 
dichloro-C6H30h, Boc-D-Phe-Pro-Arg (3-Cl-C6H40h 
can be prepared by the same procedure by coupling with the 
appropriate blocked peptide or peptide derivative. 
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EXAMPLE 8 
Cbz-Ala-Ala-ValP(OPh)z. Cbz-Ala-Ala-OH (0.294 g, 1 
mmol) was dissolved in 10 ml of dry THF and cooled to 0° 
C. Diphenyl a-amino-2-methylpropylphosphonate, (0.305 
g, 1 mmol) and DCC (0.203 g, 1 mmol) were added to this 
solution. After stirring for 8 hrs at 0° C. and overnight at 
room temperature, the solution was worked-up as described 
above. Recrystallization from chloroform-pentane gave 
0.182 g (31 % ) of crude product. A sample (0.1 g) was 
purified on preparative thin layer chromatography using 
chloroform-methanol (9:1) as eluent. The product was 
recrystallized from ethanol-pentane to give a white solid: 
mp. 93°-97° C.; one spot on TLC, R_F0.71; 31P NMR 19.44, 
19.31 ppm, ratio 1:1.11. Anal. Calcd. for 
C30H360 7N3P.EtOH; C, 61.19; H, 6.69; N, 6.69. Found: C, 
61.32; H, 6.48; N, 6.91. 
Cbz-Ala-Ala-Va!P(4-Cl-C6H40h, Cbz-Ala-Ala-van4-
0Me-C6H40h, Cbz-Ala-Ala-ValP(4-F-C6H40h, Cbz-Ala-
Ala-PheP(3,4-dimethyl-C6H30h, Cbz-Ala-Ala-NvaP(3,4-
dichloro-C6H30h, Cbz-Ala-Ala-Mer(4-Cl-C6H40h, 
Acetyl-Ala-Ala ValP(OPhh, CF3-CO-Ala-Ala-ValP(OPhh, 
Dansyl-Ala-Ala-ValP(OPhh, Tosyl-Ala-Ala-ValP(OPhh, 
Fmoc-Ala-Ala-ValP(OPhh, PhNHCO-Ala-Ala-ValP(OPhh 
EXAMPLE 6 
25 can be prepared by the same procedure by coupling with the 
appropriate blocked peptide or peptide derivative. 
Dipheny I N-(N-~-naphy lsulfonylglycy !)amino( 4-amidi-
nopheny l)methanephosphonate hydrochloride. Using the 
same procedure as example 5, 0.3 g (l.13 mmol) of ~-na- 30 
phylsulfonylglycine, 0.2 g (l.23 mmol) of CDI and 0.45 g 
(1.0 mmol) of diphenyl amino(4-amidinophenyl)methane-
phosphonate dihydrochloride (obtained in Example 3) were 
reacted and 0.21 g of product was obtained. Yield 30%; mp. 
205°-210° C. (decomp); 31P NMR, 11.76 ppm (free base), 35 
14.74 ppm (hydrochloride). Anal. Calcd. for 
C32H300 6N4 CIPS.H20: C, 56.24; H, 4.69; N, 8.20; S, 4.69. 
Found: C, 56.87; H, 4.43; N, 8.79; S, 5.06. 
EXAMPLE9 
MeO-Suc-Ala-Ala-Ala-NvaP(OPh)z. The reaction of 
0.345 g (1 mmol) of MeO-Suc-Ala-Ala-Ala-OH and 0.305 
g (1 mmol) of diphenyl a-aminobutylphosphonate gave 0.35 
g (55.3%) of product as a white solid. A 0.1 g sample was 
purified on preparative TLC as described above to give the 
product as white solid: top. 215°-218 ° C.; one spot on TLC, 
R.r=0.73; 31P NMR 20.02 ppm. Anal. Calcd. for 
C30H410 9N4P: C, 56.96; H, 6.49; N, 8.86. Found: C, 56.72; 
H, 6.58; N, 8.80. 
EXAMPLE 7 
Cbz-MetP(OPhh This compound was synthesized by the 
method described in Example 1: yield 36%; mp. 93°-95° C.; 
one spot on TLC, R.r=0.73; 31P NMR 19.68 ppm. Anal. 
Calcd. for C24H260 5NSP: C, 61.15; H, 5.52; N, 2.97; S, 
6.79. Found: C, 61.06; H, 5.60; N, 2.91; S, 6.88. 
Acetyl-Ala-Ala-Ala-NvaP(OPhh, Boc-Ala-Ala-Ala-
40 NvaP(OPhh, MeO-Suc-Ala-Ala-Ala-NvaP (4-Cl-C6H40h, 
MeO-Suc-Ala-Ala-Ala-NvaP(3,4-dimethyl-C6H30h, MeO-
Suc-Ala-Ala-Ala-NvaP(4-F-C6H40h, MeO-Suc-Ala-Ala-
Ala-NvaP(3-Cl-C6H40) 2 can be prepared by the same pro-
cedure using the corresponding tripeptide and diester ofa-
45 aminobutylphosphonate. 
Cbz-MetP(4-Cl-C6H40)2, Cbz-MetP(4-Me-C6H40h, 
Cbz-Mer(3-Me-C6H40)2, Cbz-Mer(4-F-C6H40h. Cbz-
Mer(3,4-dimethyl-C6H30h by the same procedure using 50 
corresponding tris(substituted phenyl) phosphite. 
MeO-Suc-Ala-Ala-Pro-Mer(OPh)z. The reaction of 
MeO-Suc-Ala-Ala-Pro-OH (0.64 g, 1.73 mmol), H2N-
CH(CH2CH2SCH3)P(O)(OphhHBr (0.85 g, 2 mmol), 
obtained from Cbz-Mer(OPhh, N-methylmorpholine (0.2 55 
ml, 2 mmol) and DCC (0.34 g, 1.73 mmol) under an 
atmosphere of nitrogen gave 0.5 g (42%) of product as white 
solid. A 0.2 g sample was purified on preparative TLC under 
an atmosphere of nitrogen to give product as a white solid: 
mp. 41°-43° C.; one spot on TLC, R.r=0.6; 31P NMR 19.50, 60 
19.36 ppm, ratio 1:1.32. Anal. Calcd. for 
C32H430 9N4PS.THF; C, 56.69; H, 6.69; N, 7.35; S, 4.20. 
Found: C, 57.37; H, 6.77; N, 7.76; S, 4.49. 
MeO-Suc-Ala-Ala-Pro-Mer ( 4-Cl-C6H40h, MeO-Suc-
Ala-Ala-Pro-Mer (3-Me-C6H40h, MeO-Suc-Ala-Ala-Pro- 65 
Mer(3,4-dimethyl-C6H30h can be prepared by the same 
procedure. 
EXAMPLE 10 
MeO-Suc-Ala-Ala-Ala-ValP(OPhh The reaction of 
MeO-Suc-Ala-Ala-Ala-OH (0.345 g, 1 mmol) and diphenyl 
a-amino-2-methylpropylphosphonate (0.305 g, 1 mmol) 
gave 0.3 g (47.5%)of product as white solid. A 0.1 g sample 
was purified on preparative TLC as described above to give 
the product as a white solid, which was then recrystallized 
from ethanol-hexane: mp. 197°-200° C.; one spot on TLC, 
R.r=0.63; 31P NMR 19.40, 19.24 ppm, ratio 1:0.72. Anal. 
Calcd. for C3oH410 9N4P.0.25 Hexane: C, 57.60; H, 6.85; N, 
8.61. Found: C, 57.58; H, 6.62; N, 8.36. 
Cbz-Ala-Ala-Ala-ValP (0Ph)2, MeO-Suc-Ala-Ala-Ala-
ValP ( 4-F-C6H40)z, CH3NHCO-Ala-Ala-Ala-ValP(OPh)z, 
PhNHCS-Ala-Ala-Ala-ValP(OPhh, MeO-Suc-Ala- Ala-
Ala-ValP (3-Cl-C6H40h, PhNHCO-Ala-Ala-Ala-ValP(3,4-
dimethyl-C6H30h, MeO-Suc-Ala-Ala-Ala-ValP (4-Me0-
C6H40)2 can be prepared by the same procedure using the 
corresponding tripeptide and diester of a-amino-2-methyl-
propylphosphonate. 
5,543,396 
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EXAMPLE 11 
MeO-Suc-Ala-Ala-Ala-PheP(OPhh The reaction of 
MeO-Suc-Ala-Ala-Ala-OH (0.345 g, 1 mmol) and diphenyl 
a-amino-2-phenyl-ethylphosphonate (0.353 g, 1 mmol) 
gave 0.35 g (49.l %) of the product which was purified on 
the preparative TLC, as described above. Recrystallization 
from methanol gave a whim solid: mp. 207°-210° C.; one 
spot on TLC, R;=0.69; 31P NMR 19.06, 19.01 ppm, ratio 
1:0.87. Anal. Calcd. for C34H41 0 9N4P.MeOH: C, 58.98; H, 
6.32; N, 7.86. Found: C, 58.66; H, 6.08; N, 7.96. 
MeO-Suc-Ala-Ala-Ala-PheP ( 4-Cl-C6H4 Oh, MeO-Suc-
Ala-Ala-Ala-PheP (4-Me0-C6H40)z can be prepared by the 
same procedure. 
EXAMPLE 12 
MeO-Suc-Ala-Ala-Pro-ValP (OPhh MeO-Suc-Ala-Ala-
Pro-OH(0.37 g, 1 mmol) was dissolved in 20 ml of dry THF 
and cooled to 0° C. Diphenyl a-amino-2-methylpropylphos-
phonate (0.305 g, 1 mmol) and DCC (0.203 g, 1 mmol) were 
added to this solution. After stirring for 6 hrs at 0° C. and 
overnight at room temperature, the solution was filtered and 
100 ml of ethyl acetate was added. The solution was then 
washed with 10% citric acid, 4% sodium bicarbonate and 
water successively. After drying over magnesium sulfate, the 
solution was filtered, evaporated and the residue was dis-
solved in 10 ml of THF. Trace of DCU was removed by 
filtration and after addition of 3 ml of hexane, the solution 
was allowed to crystallized. After a few days the product 
was removed by filtration and recrystallized from THF-
hexane to give 0.2 g (30%) of a white solid, mp. 83°-86° C.; 
one spot on TLC, R;=0.74; 31p NMR 19.78, 19.60 ppm, 
ratio 1:2.12. Anal. Calcd. for C32H430 9P.hexane: C, 61.30; 
H, 7.66; N, 7.53. Found: C, 61.04; H, 7.58; N, 7.69. 
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bicarbonate and water. After drying over MgS04, the mix-
ture was filtered, evaporated and residue was dissolved in 10 
ml of methylene chloride. A trace of DCU was removed by 
filtration and after addition of 30 ml of pentane, the solution 
5 was allowed to crystallize. After a few days the product was 
filtered and recrystallized from methylene chloride-hexane 
to give 1.4 g (65%) of a white solid: mp. 123°-127° C.; one 
spot on TLC, R;=0.74; 31PNMR 19.52(broad), 19.5l(broad) 
ppm. Anal. Calcd. for C29H330 6N2P: C, 64.87; H, 6.15; N, 
10 5.22. Found: C, 64.58; H, 6.23; N, 5.34. 
Boc-Val-Pro-ValP(OPhh. A solution 0.536 g (1 mrnol) of 
Cbz-Pro-ValP(OPh)2 in 50 ml of methanol with 0.1 g 5% 
Pd/C was stirred under atmosphere of hydrogen at room 
temperature for 2 hrs and filtered through celite. After 
15 addition of of Boc-Val-OH(0.217 g, 1 mmol) to the filtrate, 
the solvent was removed in vacuo. The residue was dis-
solved in 20 ml of dry THF and 0.2 g of DCC (1 mrnol) was 
added. The solution was kept at 0° C. for 6 hrs and overnight 
at room temperature. DCU was removed by filtration and the 
20 organic layer was washed with water, twice with 4% 
NaHC03, water, twice with 10% citric acid and water. After 
drying over sodium sulfate, the solvent was evaporated and 
the resulting oil was dried at low pressure for a few hours to 
give 0.45 g (72%) ofa white hydroscopic solid: mp. 62°-66° 
25 C.; one spot on TLC, R;=0.78; 31P NMR 19.64 ppm. Anal. 
Calcd. for C31H440 7N3P.H20: C, 60.10; H, 7.43. Found: C, 
60.26; H, 7.49. 
Boc-Val-Pro-Va!P(4-F-C6H40h, PhNHCS-Val-Pro-
ValP (3-Cl-C6H40)z, E-Cbz-a-Cbz-Orn-Val-Pro-ValP ( 4-F-
30 C6H40)z, Boc-Val-Pro-ValP(4-Me0-C6H40)2, Tosyl-Val-
Pro-Valp(OPh)z can be prepared by the same procedure. 
EXAMPLE 16 
PhNHCO-Ala-Ala-Pro-ValP(3-Cl-C6H40)z, PhNHCS- 35 
Ala-Ala-Pro-ValP(4-Cl-C6H40) 2, MeO-Suc-Ala-Ala-Pro-
ValP(4-Me-C6H40)z can be prepared by the same procedure. 
Cbz-Pro-PheP(OPhh The reaction of Cbz-Pro-OH (0.75 
g, 3 mrnol), diphenyl a-amino-2-phenylethylphosphonates 
(1.05 g, 3 mrnol) and DCC (0.61 g, 3 mrnol) gave 0.93 g 
(53%) of product as white solid: mp. 81°-84° C.; one spot 
on TLC, R;=0.74; 31P NMR 19.54, 19.48, 19,27 and 19.22 
ppm (diastereomers and conformers), ratio of diastereomers 
1:1. Anal. Calcd. for C33H330 6N2P: C, 67.81; H, 5.65; N, 
4.79. Found: C, 67.56; H, 5.79; N, 4.72. 
EXAMPLE 13 
40 
MeO-Suc-Ala-Ala-Pro-LeuP(OPhh The reaction of 
MeO-Suc-Ala-Ala-Pro-OH (0.37 g, 1 mmol) and diphenyl 
a-amino-3-methylbutylphosphonate (0.32 g, 1 mmol) gave 
0.38 g (50.1 %) of product as white solid: mp. 60°-64° C.; 
one spot on TLC, R1 =0.67; 
31P NMR 20.71, 20.54 ppm, 45 
ratio 1:1.33. Anal. Calcd. for C33H450 9N4P.hexane: C, 
61.74; H, 7.78; N, 7.38. Found: C, 61.04; H, 7.53; N, 7.59. 
EXAMPLE 14 
MeO-Suc-Ala-Ala-Pro-PheP(OPhh The reaction of 50 
MeO-Suc-Ala-Ala-Pro-OH (0.37 g, 1 mmol) and diphenyl 
a-amino-2-phenylethylphosphonate (0.35 g, 1 mrnol) gave 
0.4 g (50.5%) of product as a white solid: top. 53°-56° C.; 
one spot on TLC, ty--0.7; 31P NMR 19.41, 19.10 ppm, ratio 
55 1:2.47. Anal. Calcd. for C36H430 9N4P.hexane: C, 63.62; H, 
7.19; N, 7.07. Found: C, 63.42; H, 7.19; N, 7.57. 
EXAMPLE 15 
Cbz-Phe-Pro-PheP(OPhh. The reaction of Cbz-Phe-OH 
(0.3 g, 1 mrnol) with the hydrogenolysis product of Cbz-
Pro-PheP(OPh)2 (0.58 g, 1 mmol) and DCC (0.2 g, 1 mrnol), 
gave 0.4 g (54%) of a hydroscopic semi-solid product after 
a standard workup. A 0.2 g sample was purified on prepara-
tive TLC to give the product as a hydroscopic semi-solid: 
one spot on TLC, Rf=0.76; 31P NMR 19.67, 19.57, 19.32, 
19.19 and 19.07 ppm (diastereomers and conformers); ratio, 
1.0:0.34:0.82:0.73:0.92. Anal. Calcd. for 
C42H420 7N3P.2H20: C, 65.71; H, 5.99; N, 5.47. Found: C, 
65.62; H, 6.12; N, 5.27. 
EXAMPLE17 
Suc-Val-Pro-PheP(OPhh The reaction of Cbz-Val-OH 
(0.25 g, 1 mrnol), DCC (0.2 g, 1 mrnol) and the product of 
hydrogenolysis of Cbz-Pro-PheP(OPh)z (0.584 g, 1 mrnol) 
Cbz-Pro-ValP(OPh)z. Cbz-Pro-OH (0.97 g, 4 mrnol) was 
dissolved in 40 ml of dry THF and cooled to 0° C. Diphenyl 
a-amino-2-methylpropylphosphonate (1.2 g, 4 mrnol) and 
DCC (0.81 g, 4 mmol) were added to this solution. After 
stirring for 6 hrs at 0° C. and overnight at room temperature, 
the DCU was removed by filtration and 50 ml of ethyl 
acetate was added. The solution was washed successively 
twice each time with 10% citric acid, water, 4% sodium 
60 gave an oil which was dissolved in 30 ml of ethyl acetate. 
To this solution, 0.1 g (1 mmol) of succinic anhydride and 
0.1gof5% Pd/C were added and mixture was stirred under 
atmosphere of hydrogen until the TLC showed only one new 
spot. Catalyst was removed by filtration and organic layer 
65 was washed several times with water. After drying, the 
organic solvent was removed to give 0.45 g (65%) of 
product as a hydroscopic solid: mp. 50°-53° C.; one spot on 
5,543,396 
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TLC, R_r=<J.4; 31P NMR 19.75, 19.23 ppm, ratio 1:1. Anal. 
Calcd. for C34H400 3N3P.2H20: C, 59.56; H, 6.42. Found: C, 
59.59; H, 6.42. 
Suc-Val-Pro-PheP(4-MeS-C6H40h, Suc-Val-Pro-PheP(4-
Cl-C6H40h, Suc-Phe-Pro-Phep(OPhh, Sue-Val-Pro- 5 
24 
a previously described procedure (Walsh, E. N., Conversion 
of Tertiary Phosphites to Secondary Phosphonates. Diphcnyl 
Phosphonate, J. Am. Chem. Soc. 1959, 81, 3023-6). Tris(4-
chlorophenyl) phosphite was prepared from 4-chlorophenol 
and phosphorous trichloride with three equivalents of tri-
ethyl amine as a base using a modification of a previous 
procedure (McCombie, H., Saunders, B. C., Stacey, G. J., 
Esters Containing Phosphorus. Part I, J. Chem. Soc. 1945, 
381). Similarly, tris(4-fluorophenyl) phosphite was prepared 
PheP(3-F-C6H40h, Suc-Val-Pro-PheP (3,4,5-trichloro-
C6H20h, Suc-Val-Pro-PheP(2,3,4-fluoro-C6H20h, Suc-
Val-Pro-PheP (4-Me-C6H40h, Acetyl-Val-Pro-PheP(OPhh, 
CF3-CO-Val-Pro-PheP(OPhh can be prepared by the same 
procedure. 10 from 4-fluorophenol and phosphorous trichloride using one 
equivalent of triethyl amine as a base. 
EXAMPLE 18 
Cbz-AlaP(OCH2CF3h- This compound was obtained by a 
previously described method involving transesterification 15 
(Szewczyk et al., Synthesis, 1982, 409- 414). 10 ml of 
trifluoroethanol and 0.46 g of Na (0.02 mole) were mixed 
first, then 4.11 g of Cbz-AlaP(OPhh was added, and the 
mixture was stirred overnight. 3 ml of AcOH was added and 
the solvent was everaporated. The residue was dissolved in 20 
CHCl3 and washed with water, 2N NaOH and water, and 
dried over MgS04. The solvent was evaporated and the oil 
was obtained, mass spectrum m/e=423 (M+). 
Cbz-PheP(OCH2CF3)2 was prepared by the same proce-
dure, mp. 85°-87° C., mass spectrum m/e=499 (M+). Cbz- 25 
ValP(OCH2CH3h was also prepared by the same procedure 
using ethanol instead of trifuoroethanol. 
EXAMPLE 20 
Diphenyl Pyrrolidine-2-phosphonate Hydrochloride 
(HCl.ProP(OPhh, 1). This compound was synthesized from 
1-pyrroline trimer (Nomura, Y., Ogawa, K., Takeuchi, Y., 
Tomoda, S., One Step Synthesis and Structural Confirmation 
with 1-Pyrroline Trimer, Chem. Lett. 1977, 693-696) and 
diphenyl phosphite using the procedure previously 
described for the synthesis of the diethyl ester (Petrillo, E. 
W., Spitzmiller, E. R., Synthesis of 2-Phosphopyrrolidine 
and Its Substitution for Praline in an Inhibitor of Angio-
tensin-Converting Enzyme, Tet. Lett. 1979, 51, 4929). A 
mixture of 1-pyrroline trimer (17 mmol, 3.5 g) and diphenyl 
phosphite (50 mmol, 11.7 g) was heated at 85° C. for 1.5 h 
under argon to give crude diphenyl pyrrolidine-2-phospho-
nate which was dissolved in 100 ml of dry diethyl ether, 
filtered and saturated with dry gaseous HCI. The precipitated EXAMPLE 19 
Benzoyl-NHCH(4-NHrC6H4)P0(0Phh. NH2CH(4-
30 hydrochloride 1 was collected by filtration, washed with 
ether and recrystallized from acetone, to give the pure 
product as a white solid in 49% yield: mp 146°-148° C.; 
1H-NMR (D20) o(ppm): 2.0-2.5 (m, 4H), 3.40 (m, 2H), 
4.25 (m, lH), 6.90-7.30 (m, lOH); MS (FAB) m/e 304 
N02-C6H4)P0(0Ph)2.HBr was obtained by deblocking 
Cbz-NHCH (4-N02-C6H4)P0(0Phh with 30% of HBr/ 
HOAc, mp. 198°-200° C. The reaction of NH2CH(4-NO 
2-C6H4)P0(0Phh, HBr and benzoyl chloride in the pres-
ence of N-methylmorpholine gave benzoyl-NHCH(4-N02-
C6H4)PO(OPhh, mp. 157°-159° C., mass spectrum m/e= 
489 (M++l). Anal. Cale. for C26H21N20 6P: C, 63.88; H, 
4.30; N, 5.73. Found: C, 64.05; H, 4.25; N, 5.69. Hydro-
genolysis of benzoyl-NHCH(4-N02-C6H4)P0(0Phh in the 40 
presence of Pd/C catalyst gave the final product, mp. 
156°-158° C., mass spectrum m/e =458 (M+). Anal. Cale. 
35 (M-Cl)30. Anal. (C16H19N03PCI): C, H, N, Cl. 
for C26H23N20 4P: C, 68.12; H, 5.02; N, 6.11. Found: C, 
66.87; H, 5.15; N, 5.01. 
EXAMPLE 21 
Diphenyl Piperidine-2-phosphonate Hydrochloride 
(HCl.PipP(OPhh, 2). This compound was prepared from the 
trimer of 2,3,4,5-tetrahydropyridine and diphenyl phosphite 
using the procedure previously described for the synthesis of 
the diethyl ester (Solodenko, V. A., Kukhar, V. P., Synthesis 
of DL-(2-Piperidyl) Phosphonic Acid, Zh. Obsh. Khim. 
GENERAL SYNTHESIS PROCEDURES 
Benzyl carbamate, diphenyl phosphite, pyrrolidine, pip-
eridine, DCC, and all common chemicals were obtained 
from Aldrich Co., Milwaukee, Wis. Benzyloxycarbonylpro-
line (Cbz-Pro) and N'X,NE-dibenzyloxycarbonyllysine were 
obtained from Bachem Fine Chemicals, Calif. The purity of 
each new synthesized compound was checked by TLC, 
1H-NMR, mass spectroscopy (FAB), and elemental analysis. 
45 1987, 57, 2392). A mixture of the trimer (10 mmol, 2.5 g) 
and diphenyl phosphite (30 mmol, 7.0 g) was heated for 1.5 
h at 100° C. under argon. The resulted crude diphenyl 
piperidine-2-phosphonate was dissolved in 100 mL of dry 
ether, undisolved material was removed by filtration, and the 
50 solution was saturated with gaseous HCI. The precipitated 
hydrochloride 2 was collected by filtration, washed with 
ether, dried and recrystallized from acetone to give a white 
solid in 41% yield: top. 172°-174° C.; 1H-NMR (D20), o 
(ppm) 1.5-2.4 (m, 6H), 3.05 (m, lH), 3.45 (m, lH), 4.10 (m, 
In the case of multi-step synthesis the first and final products 
were checked by 1H-NMR, FAB spectra and elemental 
analysis. The solvent system used for TLC was chloroform-
acetone (9:1 ). Preparative thin-layer chromatography was 
performed with plates precoated with silica gel (Merck). The 
NMR spectra were recorded on a Varian Gemini 300 MHz 60 
instrument in CDCl3, DMSO-d6, or D20 solutions. Mass 
spectra (FAB) were recorded on a Vafion MAT Model 112S 
mass spectrometer. Elemental analysis were performed by 
Atlantic MicroLab Inc., Norcross, Ga. 
55 lH), 6.9-7.4 (m, lOH); MS (FAB) m/e 318 (M-Clt. Anal. 
(C17H21N03PC1): C, H, N, Cl. 
Di(4-chlorophenyl) phosphite and di(4-fluorophenyl) 65 
phosphite were prepared from tris(4-chlorophenyl) phos-
phite and tris(4-fluorophenyl) phosphite, respectively using 
EXAMPLE 22 
Di(4-chlorophenyl) Pyrrolidine-2-phosphonate Hydro-
chloride (HCl.ProP(OPh-4-Clh, 3). A mixture of 1-pyrroline 
trimer and di(4-chlorophenyl) phosphite was reacted using 
the procedure described for compound 1. Hydrochloride 3 
was obtained by dissolving the crude phosphonate in ether 
saturated with gaseous HCl (white solid in 30% yield): mp. 
160°-165° C. (dee.); 1H-NMR (D20) o (ppm) 1.8-2.5 (m, 
4H), 3.4 (m, 2H), 4.30 (m, lH), 7.0 (m, 4H), 7.2 (m, 4H); 
5,543,396 
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MS (FAB) m/e 372 (M- Clt. Anal. (C16H17N03PC13):C, H, 
N. 
EXAMPLE 23 
26 
Diphenyl Alanylpyrrolidine-2-phosphonate Hydrochlo-
ride (HCl.Ala-ProP(OPh) 2, 6). Cbz-Ala-ProP(OPhh was 
obtained as a thick oil in 90% yield: 1H-NMR (CDC13) Ci 
(ppm) 1.3 (dd, 3H), l.S-2.S (m, SH), 3.3-3.8 (m, 2H), 4.1 
Di( 4-chlorophenyl) Piperidine-2-phosphonate Hydro-
chloride (HCl.PipP(OPh-4-Cl)z, 4). The trimer of 2,3,4,S-
tetrahydropyridine and di(4-chlorophenyl) phosphite were 
reacted using the procedure described for compound 2. The 
phosphonate hydrochloride 4 was obtained by reaction with 
HCl as described above in SS% yield: mp.> 140° C. (dee); 
1H-NMR (D20) Ci (ppm) 1.3-2.1 (m, 6H), 3.2-3.S (m, 2H), 
4.0 (m, lH), 6.86 (m, 4H), 7.1 (m, 4H); MS (FAB) m/e 386 
(M-Clt. Anal. (exact mass, HRMS) calcd. for 
C17H19N10 3P1Cl2 m/e 386.0479, found 386.0468. 
5 (m, lH), 4.S (m, lH), S.10 (m, 2H), S.7 (dd, lH), 7.0-7.4 (m, 
lSH). Hydrogenolysis of Cbz-Ala-ProP(OPh)z gave the 
product 6 as a hygroscopic solid in 6S% yield: top. 80°-8S0 
C.; 1H-NMR (D20) Ci (ppm) 1.3-1.6 (dd, 3H), l.S-2.4 (m, 
SH), 3.3-3.7 (m, 2H), 4.2S (m, lH), 4.3S (m, lH)', 6.9-7.4 
IO (m, lOH); MS (FAB) m/e 37S (M-Clt. Anal. (exact mass, 
HRMS) calcd. for C19H24N20 4P1 m/e 37S.1474, found 
37S.1S49. 
EXAMPLE 26 
15 Diphenyl Alanylpiperidine-2-phosphonate Acetate 
EXAMPLE 24 
Di(4-fiuorophenyl) Piperidine-2-phosphonate Hydrochlo-
ride (HCl.PipP(OPh-4-Fh, S). A mixture of piperidine trimer 
(4.S g, S4 mmole) and di(4-fiuorophenyl)phosphite (14.8 g, 
SS mmole) was heated at 90°-100° C. for3 h under nitrogen. 
The resulted oil was cooled and dissolved in a mixture of SO 
mL CH2Cl2 and SO mL ether. The solution was saturated 
with dry HCl, the oil was separated and solidified after 
several hours. The solid was filtered, washed with ether and 
dried. The hygroscopic material was stirred in 200 mL dry 
ether for several hours and the yellowish solid was filtered 
and dried. The product was obtained in S4% yield ( 11.6 g) 
and used for subsequent reaction: mp. 1SS0 -16S° C. (dee); 
(CH3COOH.Ala-PipP(OPhh, 7). Cbz-Ala-PipP(OPhh was 
obtained as a thick oil in 76% yield: 1H-NMR (CDC13) Ci 
(ppm) 1.2-1.3 (dd, 3H), l.S-2.4 (m, 6H), 3.6-3.8 (m, 2H), 
4.S (g, lH), S.10 (s, 2H), S.6 (m, lH), S.8 (dd, lH), 7.0-7.4 
20 (m, lSH). Hydrogenolysis of Cbz-Ala-PipP(OPhh using one 
equiv. of acetic acid gave the product 7 as a glass-like solid 
in 82% yield: mp. 60°-70° C.; 1H-NMR (CDC13) Ci (ppm) 
1.2-1.3 (dd, 3H), l.S-2.4 (m, 6H), 2.0 (s, 3H), 3.S-4.0 (m, 
25 
2H), 4.2 (m, lH), S.6 (m, lH), 7.0-7.4 (m, lOH), 7.2 (m, 
3H); MS (FAB) m/e 389 (M-CH3COOt. Anal. (exact mass, 
HRMS) calcd. for C20H26N20 4P1 m/e 389.1630, found 
389.1639. 
1H NMR (D20) 87.2-6.8 (m, 8H), 3.6-2.9 (m, 3H), 2.2-1.4 30 
(m, 6H); MS (FAB) rn/e 3S4 (M-Clt. Anal. (exact mass, 
HRMS) calcd. for C17H19N10 3P1Cl2 m/e 3S4.1070, found 
3S4.1098. 
EXAMPLE 27 
Monophenyl Alanylpiperidine-2-phosphonate Acetate 
(CH3COOH.Ala-PipP(OH)(OPh), 8). A small amount of the 
monophenyl ester 8 was isolated in 10% yield during the 
work-up of product 7 as a white solid: mp. 17S0 -180 ° C. 
EXAMPLE 2S 35 (dee); 1H-NMR (D20) Ci (ppm) 1.3 (m, 3H), l.S-2.1 (m, 
6H), 2.1 (s, 3H), 3.S (m, 2H), 4.2 (m, lH), 4.4 (m, lH), 4.8 
(dd, lH), 7.0-7.4 (m, SH). MS (FAB) m/e 313 (M 
-CH3COOt. Anal. (exact mass, HRMS) calcd. for 
Dipeptide Synthesis: General Procedure. The hydrochlo-
ride of the phosphonates (1, 2, 3, 4 or S) (S retool) and 
triethyl amine (S mmol) were dissolved in 2S mL CH2Cl2 
and cooled to -10° C. A Cbz-blocked amino acid (S mmol) 40 
was added and the mixture was stirred at -10° C. for 1 S min. 
The coupling reagent DCC (6 mmol) in 2S mL CH2Cl2 was 
added and the mixture was stirred at -10° c. for 2 h and 20 
hat r.t. The DCU precipitate was removed by filtration and 
the filtrate was evaporated. The residue was dissolved in 100 45 
mL ethyl acetate and filtered. The organic layer was washed 
subsequently with SO mL lM HCl, water, 6% NaHC03 , and 
water, and dried over MgS04 • The filtrate was evaporated to 
give the crude dipeptide. Traces of DCU was removed by 
filtration of the crude dipeptide dissolved in 2S mL ether. 50 
The dipeptide was dried in vacuo and recrystallized from 
hexane-ether. 
The Cbz group of the di peptides were removed by hydro-
genolysis or treatment with 30% HBr in acetic acid. The 
Cbz-blocked di peptide (1-2 mmol) was dissolved in 100 mL 55 
methanol, one equivalent of cone. hydrochloric acid (1-2 
mmol) and S% Pd on carbon (O.S-1.0 g) were added, and the 
mixture was hydrogenated at r.t. for 2-3 h. After hydroge-
nation, the catalyst was removed and the filtrate was evapo-
rated to give the deblocked dipeptide hydrochloride, which 60 
was recrystallized from methanol-ether, or ether. The Cbz-
blocked dipeptide (1 mmol) can also be treated with 1 mL 
30% HBr/AcOH and stirred at r.t. for 1 h. The mixture was 
protected against moisture during stirring. The solution was 
diluted with SO mL dry ether and kept at 0° C. for 1-2 h. The 65 
hydrobromide of dipeptide precipitated, was filtered, 
washed with dry ether, and dried as a yellow-brown solid. 
C14H22N20 4P1 m/e 313.1317, found 313.1S18. 
EXAMPLE 28 
Diphenyl Phenylalanylpyrrolidine-2-phosphonate Hydro-
bromide (HBr.Phe-ProP(OPhh, 9). Cbz-Phe-ProP(OPhh 
was obtained as a thick oil which partially solidified in 61 % 
yield: 1H-NMR (CDC13) Ci (ppm) 1.0-2.0 (m, 4H), 3.2S (d, 
2H), 3.0-3.S (m, 3H), 4.7 (m, lH), S.OS (m, lH), S.lS (s, 
2H), S.3S (m, lH), 7.0-7.4 (m, 20H). Deblocking of Cbz-
Phe-ProP(OPh)2 with 30% HBr/AcOH gave the product 9 as 
a yellow-brown hygroscopic solid in 33% yield: mp.>140° 
C. (dee.); 1H-NMR (D20) Ci 1.0-2.0 (m, 4H), 3.0-3.4 (m, 
3H), 3.3 (d, 2H), 4.3 (m, lH), 4.7 (m, lH), 7.0-7.4 (m, lSH); 
MS (FAB) m/e 4Sl (M-Brt. Anal. (exact mass, HRMS) 
calcd. for C25H28N20 4P1 m/e 4Sl.1786, found 4Sl.1769. 
EXAMPLE 29 
Diphenyl Lysylpyrrolidine-2-phosphonate Dihydrobro-
mide (2HBr.Lys-ProP(OPhh, 10). The lysine derivative 
Cbz-Lys(Cbz)-OH was reacted with phosphonate 1 to give 
Cbz-Lys(Cbz)-ProP(OPh)2 as a thick oil in 86% yield: 
1 H-NMR (CDC3 ) Ci (ppm) 1.0-2.S (m, 8H), 3.0-4.0 (m, 4H), 
4.S (m, lH), 4.9 (m, lH), S.1 (2s, 4H), S.S-S.8 (dd, 2H), 
7.0-7.4 (m, 20H). Treatment of Cbz-Lys(Cbz)-ProP(OPh) s 
with 30% HBr/ AcOH gave the product 10 as a yellow brown 
hygroscopic solid in 64% yield: mp. >8S° C. (dee.); 
1H-NMR (D20) 15 (ppm) 1.2-2.S (m, SH), 2.8-3.0 (m, 4H), 
3.SS (t, lH), 4.1-4.S (m, 2H), 7.0-7.S (m, lOH); MS (FAB) 
5,543,396 
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C20H24N20 4PF2 m/e 425.1442, found. 425.1290. m/e 432 (M -H -2Brt. Anal. (exact mass, HRMS) calcd. 
for C22H31N30 4P1 m/e 432.2052, found 432.2059. 
EXAMPLE 30 
Diphenyl Lysylpiperidine-2-phosphonate Dihydrochlo-
ride (2HCl.Lys-PipP(OPh)z, 11). The lysine derivative Cbz-
Lys(Cbz)-OH was reacted with phosphonate 2 to give diphe-
nyl Cbz-Lys(Cbz)-PipP(OPh)z as a thick oil in 65% yield: 
1H-NMR (CDC13) 8 (ppm) 1.0-2.0 (m, 12H), 3.0-3.2 (m, 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 
5 and their equivalents. 
10 2H), 3.4-3.S (m, 2H), 4.4-4.S (m, lH), 5.1(2s,4H), 5.5-5.9 
(m, 2H), 7.0-7.5 (m, 20H). Hydrogenolysis of Cbz-Ly-
s(Cbz)-PipP(OPh)z gave the product 11 as a white solid in 
54% yield: mp. 110°-115° C. (dee.); 1H-NMR (D20) 8 
(ppm) 1.3-2.l (m, 12H), 2.S-3.0 (m, 2H), 3.3-3.7 (m, 2H), 
4.3-4.5 (m, lH), 7.0-7.4 (m, lOH); MS (FAB) m/e 446 15 
(M-H-2Clt. Anal. (exact mass, HRMS) calcd. for 
C23H33N30 4P1 m/e 446.220S, found 446.2213. 
EXAMPLE 31 
Di(4-chlorophenyl) Alanylpyrrolidine-2-phosphonate 
Hydrochloride (HCl-Ala-ProP(OPh-4-Cl)z, 12). Benzyloxy-
carbonylalanine (Cbz-Ala) was reacted with phosphonate 3 
20 
to give Cbz-Ala-ProP(OPh-4-Cl)z (12a) as a semi-solid in 
41% yield: 1H-NMR (CDC13 ) 8 (ppm) 1.25-1.35 (dd, 3H), 25 
l.S-2.5 (m, 4H), 3.3-3.9 (m, 2H), 4.55 (m, lH), 5.0 (m, lH), 
5.1 (s, 2H), 5.5-5.7 (dd, lH), 7.0-7.4 (m, 13H); MS 12 as 
a hygroscopic white solid in 53% yield: mp. SS 0-91° C.; 
1H-NMR (D20) 8 (ppm) 1.25-1.35 (dd, 3H), 1.7-2.2 (m, 
4H), 3.2-3.6 (m, 2H), 4.25 (q, lH), 4.6-4.S (m, lH), 6.7-7.0 30 
(m, SH), MS (FAB) m/e 443 (M-Clt. Anal. (Exact mass, 
HRMS) calcd. for C19H22N20 4Cl2P1 m/e 443.0694, found 
443.0649. 
What is claimed is: 
1. A compound having the following structures: 
(x~ <'x 
N OZ N-< OZ I I / I 
AA j°p \ or AA j°p \ 
o oz1 o oz1 
or a pharmaceutically acceptable salt thereof, wherein 
Zand Z1 are the same or different and are selected from 
the group consisting of cl-6 perfluoralkyl, phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, and pentafluorophenyl; 
J is selected from the group consisting of halogen cl-6 
alkyl, C1_6 perfluoroalkyl, C1_6 alkoxy, N02, CN, OH, 
C02H, amino C1_6 alkylamino, C2_12 dialkylamino, 
C1_6 acyl, and C1_6 alkoxy-CO-, and C1_6 alkyl-
S-; 
X is selected from the group consisting of 
(a) a single bond, 
(b)-CH2-, 
(c) -CH2CH2-, (d) -CH2CH2CH2-, (e) -CH2CH2CH2CH2-, 
(f)-Y-
(g) -CH2-Y-, 
EXAMPLE 32 
(h) -Y-CH2-, and (i)-H, H-, 
35 wherein Y is 0 or S; and 
Di(4-chlorophenyl) Alanylpiperidine-2-phosphonate 
Hydrochloride (HCl.Ala-PipP(OPh-4-Cl)z, 13). Benzyloxy-
carbonylalanine (Cbz-Ala) was reacted with phosphonate 4 
to give Cbz-Ala-PipP(OPh-4-Cl)z (13a) as a thick oil in 3S% 
yield: 1H-NMR (CDC13) 8 (ppm) 1.25-1.35 (2d, 3H), 
40 
1.4-2.3 (m, 6H), 3.3-3.9 (m, 2H), 4.5-4.S (m, lH), 5.1 (s, 
2H), 5.4 (m, lH), 5.S (dd, lH), 7.0-7.4 (m, SH), 7.35 (s, 5H); 
MS (FAB) m/e 591 (M+lt. Hydrogenolysis of Cbz-Ala-
PipP(OPh-4-Cl)z gave 13 as a hygroscopic solid in 49% 
yield: top. 110°-115° C. (dee.); 1H-NMR (D20) 8 (ppm) 45 
1.35 (d, 3H), 1.1-2.0 (m, 6H), 3.35 (m, 2H), 3.70 (m, lH), 
4.40 (m, lH), 6.S-7.4 (m, SH); MS (FAB) m/e 457 (M-Clt. 
Anal. (exact mass, HRMS) calcd. for C20H24N20 4Cl2P 1 m/e 
457.0S51, found 457.0S34. 
50 
EXAMPLE 33 
Di(4-fluorophenyl) Alanyl-piperidine-2-phosphonate 
Hydrochloride (HCl.Ala-PipP(OPh-4-F)z, 14). Benzyloxy-
carbonylalanine (Cbz-Ala) was reacted with phosphonate 5 55 
to give Cbz-Ala-PipP(OPh-4-F)z (14a) as a thick oil in 25% 
yield: TLC (CHC13:Acetone=9:1) R_F().45; 1H NMR (DMSO) 8 7.35(s, 5H), 7.4-6.9 (m, SH), 5.4-5.1 (m, lH), 5.0 
(s, 2H), 4.7-4.3 (m, lH), 3.9 (m, lH), 3.5-3.1 (m,2H), 
2.0-1.1 (m, 6H), 1.25 (rid, 3H); MS (FAB) m/e 559 (M+Ht. 60 
The hydrogenolysis of 14a (1.3 g, 2.3 mmole) in methanol 
in the presence of 1 equivalent of HCl and 5% Pd/C gave a 
hygroscopic solid which was recrystallized from methanol 
and ether in 57% yield (0.6 g): mp. 105°-115° C. (dee); 1H 
NMR (D20) 8 6.S5-6.55 (m, SH), 4.5-4.25 (m, 2H), 3.7-3.2 65 
(m, 2H), 2.0-1.1 (m, 6H), 1.46-1.32 (d, 3H); MS (FAB) m/e 
425 (M-Clt. Anal. (exact mass, HRMS) calcd. for 
AA is attached through the carboxylic end and is selected 
from the group consisting of 
(a) the structure NH2-CHR-CO-
where R is selected from the group consisting of C1_6 
alkyl and cl-6 fluorinated alkyl, 
(b) a side chain blocked or unblocked alpha amino acid 
residue with the L, D or DL configuration at the 
a-carbon atom selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryp-
tophan, serine, threonine, cysteine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, argi-
nine, histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
omithine, homoarginine, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-ben-
zylcysteine, [NH2-CH(CH2CHEt2)-COOH] 
NH2-CH(CH2CHEt2)-CO-, alpha-
aminoheptanoic acid, [NH2-CH(CH2-1-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, NH2-
CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-
cyclobutyl) -COOH, NH2-CH(CH2-cyclopro-
pyl)-COOH,]NH2-CH(CH2-1-napthyl)-CO-, 
NH2-CH (CHz-2-napthyl)-CO-, NH2-
CH(CH2-cyclohexyl)-CO-, NH2-CH(CH2-cy-
clopentyl)-CO-, NH2-CH(CH2-cyclobutyl)-
CO-, NH2-CH(CH2-cyclopropyl)-C0-5,5,5-
trifluoroleucine, and hexafluoroleucine, 
(c) an amino acid residue selected from the group con-
sisting of beta-alanine, glycine, epsilon-aminocaproic 
acid, and sarcosine, and 
5,543,396 
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(d) C6H5CH20CO-. 
2. A compound having the following structures: 
(x~ <'x 
N OZ N-< OZ 
I I I I 
AA ;fp\ or AA ;fp\ 
o oz1 o oz1 
or a pharmaceutically acceptable salt thereof, wherein 
Z and Z1are the same or different and are selected from 
the group consisting of cl-6 perfiuoralkyl, phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
5 
10 
phenyl trisubstituted with J, and pentafiuorophenyl; 15 
J is selected from the group consisting of halogen C1_6 
alkyl, C1_6perfiuoroalkyl, C1_6 alkoxy, N02, CN, OH, 
C02H, amino, C1_6alkylamino, C2_12 dialkylamino, 
C1_6 acyl, and C1_6 alkoxy-CO-, and C1_6alkyl-
S-; 
X is selected from the group consisting of -CH2- and 
-CH2CH2- and, 
AA is attached through the carboxylic end and is selected 
from the group consisting of 
(a) the structure NH2-CHR-CO-
where R is selected from the group consisting of C1_6 
alkyl and cl-6 fluorinated alkyl, 
20 
25 
(b) a side chain blocked or unblocked alpha amino acid 
residue with the L, D or DL configuration at the 30 
a-carbon atom selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryp-
tophan, serine, threonine, cysteine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, argi- 35 
nine, histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
omithine, homoarginine, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-ben-
zylcysteine, [NH2-CH(CH2CHEt2)-COOH] 40 
NH2-CH(CH2CHEti)-CO-, alpha-
aminoheptanoic acid, [NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CHr2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, NH2-
CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2- 45 
cyclobutyl)-COOH, NH2-CH(CH2-cyclopro-
pyl)-COOH,]NH2-CH(CH2-l-napthyl)-CO-, 
NH2-CH (CH2-2-napthyl)-CO-, NH2-
CH(CH2-cyclohexyl)-CO-, NH2-CH(CH2-cy-
clopentyl)-CO-, NH2-CH(CH2-cyclobutyl)- 50 
CO-, NH2-CH(CH2-cyclopropyl)-C0-5,5,5-
trifluoroleucine, and hexafluoroleucine, 
(c) an amino acid residue selected from the group 
consisting of beta-alanine, glycine, epsilon-aminoca-
proic acid, and sarcosine, 
(d) H, and 
(e) C6H5CH20CO-. 
3. A compound according to claim 2 wherein 
55 
Zand Z1 are selected from the group consisting of phenyl, 
phenyl substituted with J, and phenyl disubstituted with 60 
J. 
4. A compound according to claim 3 wherein 
AA is attached through the carboxylic end and is selected 
from the group consisting of 
(a) the structure NH2-CHR-CO- 65 
where R is selected from the group consisting of C1_6 
alkyl and cl-6 fluorinated alkyl, 
30 
(b) a side chain blocked or unblocked alpha amino acid 
residue with the I, D or DL configuration at the 
a-carbon atom selected from the group consisting of 
alanine, voline, ieucine, isoleucine, proline, 
methionine, methionine sulfoxide, phenylalanine, 
tryptophan, serine, threonine, cysteine, asparagine, 
glutamine, aspartic acid, glutamic acid, 1 ysine, argi-
nine, histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
omithine, homoarginine, 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-ben-
zylcysteine, [NH2-CH(CH2CHEt2)-COOH]NHr 
CH(CH2CHEt2)-CO-, alpha-aminoheptanoic 
acid, [Nl)i-CH(CH2-l-napthyl)-COOH, NH2-
CH(CHr2-napthyl)-COOH, NH2-CH(CH2-cy-
clohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH,] NH2-
CH(CH2-l-naphyl)-CO-, NH2-CH(CH2-2-
napthyl)-CO-, NH2-CH(CH2-cyclohexyl)-
CO-, NH2-CH(CH2-cyclopentyl)-CO-, 
NH2-CH(CH2-cyclobutyl)-CO-, NH2-
CH(CH2-cyclopropyl)-CO-, 5,5,5-trifluoroleu-
cine, and hexafiuoroleucine, and 
(c) an amino acid residue selected from the group 
consisting of beta-alanine, glycine, epsilon-aminoca-
proic acid, and sarcosine. 
5. A compound or pharmaceutically acceptable salt of the 
compound selected from the group consisting of: 
(a) diphenyl pyrrolidine-2-phosphonate hydrochloride 
(HCl.ProP(OPh)i), 
(b) diphen_xl piperidine-2-phosphonate hydrochloride 
(HCl.Pip (OPh)i), 
(c) di(4-chlorophenyl) pyrrolidine-2-phosphonate hydro-
chloride (HCl.ProP(OPh-4-Cl)i), 
(d) di(4-chlorophenyl) piperidine-2-phosphonate hydro-
chloride (HCl.PipP(OPh-4-Cl)i), 
(e) di(4-fluorophenyl) piperidine-2-phosphonate hydro-
chloride (HCl.PipP(OPh-4-F)i), 
(f) diphenyl alanylpyrrolidine-2-phosphonate hydrochlo-
ride (HCl.Ala-ProP (OPh)i), 
(g) Cbz-Ala-ProP(OPhh, 
(h) Ala-PipP(OPh)i, 
(i) Cbz-Ala-Pipp(OPh}i, 
(j) Phe-ProP(OPh}i, 
(k) Cbz-Phe-ProP(OPhh, 
(1) Lys-ProP(OPh)2 , 
(m) Cbz-Lys(Cbz)-ProP(OPh)2 , 
(n) Lys-Pipp(OPhh, 
(o) Cbz-Lys(Cbz)-PipP(OPhh, 
(p) Ala-ProP(OPh-4-Cl)i, 
(q) Cbz-Ala-ProP(OPh-4-Cl)i, 
(r) Ala-Pipp(OPh-4-Clh, 
(s) Cbz-Ala-Pipp(OPh-4-Cl)i, 
(t) Ala-PipP(OPh-4-F}i, and 
(u) Cbz-Ala-PipP(OPh-4-Fh 
6. A method of inhibiting dipeptidyl peptidase IV in 
mammals consisting of treating a mammal with a therapeu-
tically effective amount of the compound in claim 1. 
7. A method of preventing tissue transplant rejection in 
mammals consisting of treating a mammal with a therapeu-
tically effective amount of the compound in claim 1. 
8. A compound according to claim 1 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 
the L configuration at the a-carbon. 
5,543,396 
31 
9. A compound according to claim 1 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 
the D configuration at the a-carbon. 
10. A compound according to claim 1 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 5 
the DL configuration at the a-carbon. 
11. A compound according to claim 4 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 
the L configuration at the a-carbon. 
32 
12. A compound according to claim 4 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 
the D configuration at the a-carbon. 
13. A compound according to claim 4 wherein AA is a side 
chain blocked or unblocked alpha amino acid residue with 
the DL configuration at the a-carbon. 
* * * * * 
